Effects of Extended-Release Niacin with Laropiprant in

New England Journal of Medicine
371, 203-212
DOI: 10.1056/nejmoa1300955

Citation Report

#	Article	IF	Citations
1	Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. Therapeutics and Clinical Risk Management, 2014, 10, 875.	0.9	13
2	Current Treatment of Familial Hypercholesterolaemia. European Cardiology Review, 2014, 9, 76.	0.7	16
3	Diabetic Dyslipidemia - Role of Saroglitazar. , 2014, 4, .		1
4	Spotlight on HDL biology: new insights in metabolism, function, and translation. Cardiovascular Research, 2014, 103, 337-340.	1.8	16
6	Reconstituted High-Density Lipoprotein Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1800-1802.	1.1	7
7	Fibrates and niacin: is there a place for them in clinical practice?. Expert Opinion on Pharmacotherapy, 2014, 15, 2673-2680.	0.9	11
8	Inflammatory therapeutic targets in coronary atherosclerosisÃ¢â‚¬â€from molecular biology to clinical application. Frontiers in Physiology, 2014, 5, 455.	1.3	28
9	Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial. New England Journal of Medicine, 2014, 371, 288-290.	13.9	73
10	Niacin for Reduction of Cardiovascular Risk. New England Journal of Medicine, 2014, 371, 1940-1944.	13.9	7
11	Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. Journal of Lipid Research, 2014, 55, 2007-2021.	2.0	80
12	Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia. American Journal of Cardiovascular Drugs, 2014, 14, 471-478.	1.0	11
13	Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. Journal of Lipid Research, 2014, 55, 2167-2177.	2.0	47
14	Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 913-947.	1.2	85
15	Alice in Lipidland. Journal of the American College of Cardiology, 2014, 64, 2193-2195.	1.2	2
16	Strengthening the Achilles Heel of High-Risk Plaquesâˆ—. Journal of the American College of Cardiology, 2014, 64, 2218-2221.	1.2	0
17	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 64, 2525-2540.	1.2	192
18	Variance in niacin response in individuals with elevated lipoprotein(a). Journal of Clinical Lipidology, 2014, 8, 646-647.	0.6	1
19	Reply. Journal of Clinical Lipidology, 2014, 8, 647.	0.6	0

#	Article	IF	Citations
20	Why do statins reduce cardiovascular disease more than other lipid modulating therapies?. European Journal of Clinical Investigation, 2014, 44, 1135-1140.	1.7	16
21	Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology, 2014, 9, 441-470.	0.4	7
22	What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?. Current Opinion in Lipidology, 2014, 25, 423-430.	1.2	22
23	HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. Global Cardiology Science & Practice, 2014, 2014, 37.	0.3	3
24	Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence. Research and Reports in Endocrine Disorders, 0, , 1.	0.4	0
25	Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovascular Diabetology, 2014, 13, 159.	2.7	135
26	Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages. Journal of Lipid Research, 2014, 55, 2501-2508.	2.0	63
27	Emerging drugs for hyperlipidaemia: an update. Expert Opinion on Emerging Drugs, 2014, 19, 471-488.	1.0	5
28	Niacin fails to reduce vascular events in large randomised trial. BMJ, The, 2014, 349, g4774-g4774.	3.0	4
29	Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis, 2014, 237, 696-704.	0.4	27
31	Nontraditional Serum Lipid Variables and Recurrent Stroke Risk. Stroke, 2014, 45, 3269-3274.	1.0	41
32	HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. New England Journal of Medicine, 2014, 371, 2383-2393.	13.9	1,113
33	HDL and coronary heart diseaseâ€"novel insights. Nature Reviews Cardiology, 2014, 11, 559-560.	6.1	9
34	Cardiovascular preventionâ€"end of the road for niacin?. Nature Reviews Endocrinology, 2014, 10, 646-647.	4.3	9
35	LDL cholesterol: controversies and future therapeutic directions. Lancet, The, 2014, 384, 607-617.	6.3	229
36	HDL and cardiovascular disease. Lancet, The, 2014, 384, 618-625.	6.3	540
37	Dyslipidaemia in perspective. Lancet, The, 2014, 384, 566-568.	6.3	4
38	Triglycerides and cardiovascular disease. Lancet, The, 2014, 384, 626-635.	6.3	1,005

#	Article	IF	Citations
39	Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis, 2014, 237, 319-335.	0.4	39
40	Niacin and HDL Cholesterol â€" Time to Face Facts. New England Journal of Medicine, 2014, 371, 271-273.	13.9	43
41	Niacinâ€"laropiprant fails to reduce the risk of vascular events. Nature Reviews Cardiology, 2014, 11, 558-558.	6.1	0
42	Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radical Biology and Medicine, 2014, 76, 261-277.	1.3	53
44	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
45	Familial hyperlipidaemia. British Journal of Cardiac Nursing, 2015, 10, 394-402.	0.0	0
46	High prevalence of raised lipoprotein(a) in patients with refractory angina. Global Cardiology Science & Practice, 2015, 2015, 28.	0.3	5
47	Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S26624.	0.6	19
48	PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?. Clinical Pharmacology and Therapeutics, 2015, 98, 590-601.	2.3	4
49	Improving the odds: ezetimibe and cardiovascular disease. International Journal of Clinical Practice, 2015, 69, 390-395.	0.8	2
50	PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Medicine, 2015, 13, 258.	2.3	32
51	Hyperlipidemia and cardiovascular disease. Current Opinion in Lipidology, 2015, 26, 468-469.	1.2	6
52	Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology, 2015, 26, 484-491.	1.2	35
53	Effect of Extendedâ€Release Niacin on Highâ€Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statinâ€Treated Patients. Journal of the American Heart Association, 2015, 4, e001508.	1.6	21
54	New worldwide lipid guidelines. Current Opinion in Cardiology, 2015, 30, 447-453.	0.8	4
55	Long-term follow-up of lipid-lowering trials. Current Opinion in Lipidology, 2015, 26, 572-579.	1.2	18
56	Statin intolerance. Current Opinion in Lipidology, 2015, 26, 492-501.	1.2	32
57	What an anticardiovascular diet should be in 2015. Current Opinion in Lipidology, 2015, 26, 270-275.	1.2	16

#	Article	IF	Citations
58	Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia. Medicine (United States), 2015, 94, e881.	0.4	5
59	Prioritizing health outcomes in a limited world. Current Opinion in Lipidology, 2015, 26, 188-194.	1.2	2
60	Recent developments in modulating atherogenic lipoproteins. Current Opinion in Lipidology, 2015, 26, 369-375.	1.2	8
61	Mendelian randomization studies. Current Opinion in Lipidology, 2015, 26, 566-571.	1.2	56
62	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
63	Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease. European Journal of Clinical Investigation, 2015, 45, 1092-1097.	1.7	5
64	Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?. Medical Science Monitor, 2015, 21, 2156-2162.	0.5	24
65	The Regression of Atherosclerosis: The Power of Multimodality Imaging. Journal of Clinical & Experimental Cardiology, 2015, 06, .	0.0	1
66	Low-Normal Thyroid Function and Novel Cardiometabolic Biomarkers. Nutrients, 2015, 7, 1352-1377.	1.7	39
67	Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?. Vascular Health and Risk Management, 2015, 11, 203.	1.0	6
68	Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. Vascular Health and Risk Management, 2015, 11, 165.	1.0	6
69	Combination pharmacotherapy in lipid management. Journal of the Korean Medical Association, 2015, 58, 745.	0.1	0
70	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. Endocrine Practice, 2015, 21, 1403-1414.	1.1	22
71	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids in Health and Disease, 2015, 14, 45.	1.2	13
72	Drugs that Affect Lipid Metabolism. Side Effects of Drugs Annual, 2015, 37, 559-565.	0.6	3
73	The Effects of Statins on Infections after Stroke or Transient Ischemic Attack: A Meta-Analysis. PLoS ONE, 2015, 10, e0130071.	1.1	6
74	Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs. PLoS ONE, 2015, 10, e0136934.	1.1	3
75	Variation in the Phosphoinositide 3-Kinase Gamma Gene Affects Plasma HDL-Cholesterol without Modification of Metabolic or Inflammatory Markers. PLoS ONE, 2015, 10, e0144494.	1.1	22

#	Article	IF	Citations
76	The role of the lymphatic system in cholesterol transport. Frontiers in Pharmacology, 2015, 6, 182.	1.6	58
77	HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Frontiers in Pharmacology, 2015, 6, 187.	1.6	32
78	Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia. Disease Markers, 2015, 2015, 1-8.	0.6	6
79	All for Statins and Statins for All; An Update. Current Pharmaceutical Design, 2015, 22, 18-27.	0.9	19
80	Vitamin paradox in obesity: Deficiency or excess?. World Journal of Diabetes, 2015, 6, 1158.	1.3	32
81	TRPV1 Channels Are Involved in Niacin-induced Cutaneous Vasodilation in Mice. Journal of Cardiovascular Pharmacology, 2015, 65, 184-191.	0.8	9
82	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397.	13.9	3,337
83	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. European Heart Journal, 2015, 36, 2110-2118.	1.0	55
84	Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery. International Journal of Pharmaceutics, 2015, 490, 55-64.	2.6	27
85	Proof That Lower Is Better â€" LDL Cholesterol and IMPROVE-IT. New England Journal of Medicine, 2015, 372, 2448-2450.	13.9	108
86	Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. Current Atherosclerosis Reports, 2015, 17, 43.	2.0	27
88	Therapeutic Options: Lifestyle Measures and Pharmacological Approaches. , 2015, , 417-431.		0
89	Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study). American Journal of Cardiology, 2015, 115, 890-894.	0.7	36
90	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology, 2015, 763, 48-63.	1.7	44
91	The appropriate clinical use of niacin in the treatment of dyslipidemia. Clinical Lipidology, 2015, 10, 17-22.	0.4	1
92	Twenty-five years of statins: where do we go from here?. Clinical Lipidology, 2015, 10, 33-45.	0.4	2
93	Niacin as antidyslipidemic drug. Canadian Journal of Physiology and Pharmacology, 2015, 93, 1043-1054.	0.7	27
94	Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney International, 2015, 87, 1250-1257.	2.6	46

#	Article	IF	Citations
95	Lipoproteins and Cardiovascular Disease Risk. Contemporary Endocrinology, 2015, , 57-65.	0.3	0
96	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 507-513.	5.5	389
97	Immediate release niacin effect at stratified lipid levels. IJC Metabolic & Endocrine, 2015, 9, 48-53.	0.5	0
98	Gender differences in lipid goal attainment among Chinese patients with coronary heart disease: insights from the DYSlipidemia International Study of China. European Heart Journal Supplements, 2015, 17, B39-B46.	0.0	0
99	Lipid Management in Diabetes with a Focus on Emerging Therapies. Canadian Journal of Diabetes, 2015, 39, S183-S190.	0.4	8
100	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics, 2015, 37, 2732-2750.	1.1	7
101	Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. Clinical Therapeutics, 2015, 37, 2751-2769.	1.1	27
102	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Journal of the American College of Cardiology, 2015, 66, 2201-2210.	1.2	105
103	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology, 2015, 9, S1-S122.e1.	0.6	430
104	The past, present and future of lipid-lowering therapy. Clinical Lipidology, 2015, 10, 481-498.	0.4	6
105	Introduction to Clinical Trials. , 2015, , 1-23.		14
106	Humble kidneys predict mighty heart troubles. Lancet Diabetes and Endocrinology,the, 2015, 3, 489-491.	5.5	16
107	Placing HPS2-THRIVE in context using Bayesian analysis. International Journal of Cardiology, 2015, 195, 203-204.	0.8	1
108	Is HPS2-THRIVE the death knell for niacin?. Journal of Clinical Lipidology, 2015, 9, 343-350.	0.6	9
109	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	0.6	5
110	Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. Journal of Clinical Lipidology, 2015, 9, 832-836.	0.6	6
111	The year in cardiology 2014: coronary intervention. European Heart Journal, 2015, 36, 347-352.	1.0	1
112	Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. Metabolic Syndrome and Related Disorders, 2015, 13, 1-21.	0.5	26

#	Article	IF	Citations
113	Ï‰-3 carboxylic acids for hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2015, 16, 123-133.	0.9	8
114	New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis, 2015, 239, 483-495.	0.4	314
115	The Cholesterol Lowering Atherosclerosis Study (CLAS): What it tells us about niacin/colestipol therapy. Journal of Clinical Lipidology, 2015, 9, 11-13.	0.6	2
116	Management of lipid disorders in patients living with HIV. Journal of Clinical Pharmacology, 2015, 55, 957-974.	1.0	35
117	Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness. Journal of Clinical Lipidology, 2015, 9, 113.	0.6	0
118	Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research, 2015, 58, 14-25.	5.3	45
119	Extreme Nonfasting Remnant Cholesterol vs Extreme LDL Cholesterol as Contributors to Cardiovascular Disease and All-Cause Mortality in 90000 Individuals from the General Population. Clinical Chemistry, 2015, 61, 533-543.	1.5	133
120	Current Drug Treatment of Hyperlipidemia in Older Adults. Drugs and Aging, 2015, 32, 127-138.	1.3	10
121	Early investigational drugs targeting PPAR-Î± for the treatment of metabolic disease. Expert Opinion on Investigational Drugs, 2015, 24, 611-621.	1.9	41
122	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Canadian Pharmacists Journal, 2015, 148, 21-28.	0.4	6
123	Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia, 2015, 58, 799-808.	2.9	98
124	Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. Rheumatology International, 2015, 35, 1059-1067.	1.5	19
125	Primary Prevention of Atherosclerotic Cardiovascular Disease. Annals of Pharmacotherapy, 2015, 49, 484-493.	0.9	9
126	Niacin and Progression of CKD. American Journal of Kidney Diseases, 2015, 65, 785-798.	2.1	24
127	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature. Atherosclerosis, 2015, 242, 647-656.	0.4	56
128	Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?. Diabetes, 2015, 64, 2344-2345.	0.3	7
129	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. Journal of the American College of Cardiology, 2015, 65, 2638-2651.	1.2	156
130	Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. Journal of Clinical Lipidology, 2015, 9, 313-325.	0.6	11

#	Article	IF	Citations
131	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Journal of Clinical Lipidology, 2015, 9, 496-497.	0.6	1
132	Combined dyslipidemia in childhood. Journal of Clinical Lipidology, 2015, 9, S41-S56.	0.6	42
134	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. Canadian Journal of Cardiology, 2015, 31, 585-587.	0.8	8
135	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Nonâ€“High-Density Lipoprotein Cholesterol. Circulation, 2015, 132, 667-676.	1.6	41
136	Fatty acids and the risk of death during acute myocardial ischaemia. Clinical Science, 2015, 128, 349-355.	1.8	18
137	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs, 2015, 75, 1201-1228.	4.9	18
138	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet, The, 2015, 386, 1472-1483.	6.3	386
139	Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease. Thrombosis Research, 2015, 136, 493-503.	0.8	36
140	Ezetimibeâ€“Statin Combination to Reduce Cardiovascular Events: The Evidence Base. Metabolic Syndrome and Related Disorders, 2015, 13, 327-328.	0.5	0
141	PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Cardiovascular Drugs and Therapy, 2015, 29, 295-308.	1.3	18
142	HDL function as a predictor of coronary heart disease events: time to re-assess the HDL hypothesis?. Lancet Diabetes and Endocrinology,the, 2015, 3, 488-489.	5.5	5
143	The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovascular Research, 2015, 106, 184-193.	1.8	35
144	Screening and treatment of familial hypercholesterolemia â€“ Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis, 2015, 241, 597-606.	0.4	34
145	Cardiovascular Disease Risk Assessment and Prevention. Medical Clinics of North America, 2015, 99, 711-731.	1.1	38
147	A Pilot Trial to Examine the Effect of High-Dose Niacin on Arterial Wall Inflammation Using Fluorodeoxyglucose Positron Emission Tomography. Academic Radiology, 2015, 22, 600-609.	1.3	3
148	Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist. European Journal of Pharmacology, 2015, 756, 1-7.	1.7	17
149	Statins, atherosclerosis regression and HDL: Insights from within the plaque. International Journal of Cardiology, 2015, 189, 168-171.	0.8	15
150	Role for Combination Therapy in Diabetic Dyslipidemia. Current Cardiology Reports, 2015, 17, 32.	1.3	26

#	Article	IF	Citations
151	Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis, 2015, 240, 520-525.	0.4	18
152	Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance. Drugs, 2015, 75, 713-722.	4.9	14
153	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1500-1509.	13.9	1,352
154	High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity. Progress in Cardiovascular Diseases, 2015, 58, 32-40.	1.6	71
155	Lipid Management in Human Immunodeficiency Virus. Cardiology Clinics, 2015, 33, 277-298.	0.9	1
156	Lipoprotein(a) â€“ An independent causal risk factor for cardiovascular disease and current therapeutic options. Atherosclerosis Supplements, 2015, 18, 263-267.	1.2	54
157	Effect of Naturally Random Allocation toÂLower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms inÂNPC1L1, HMGCR, or Both. Journal of the American College of Cardiology, 2015, 65, 1552-1561.	1.2	324
158	Targeting Lipoprotein (a): an Evolving Therapeutic Landscape. Current Atherosclerosis Reports, 2015, 17, 502.	2.0	8
159	Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet, The, 2015, 385, 2153-2161.	6.3	92
160	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	0.6	632
161	Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 191, 138-148.	0.8	39
162	Obesity and Ischemic Heart Disease. Circulation Research, 2015, 116, 570-571.	2.0	7
163	Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology, 2015, 192, 72-81.	0.8	28
164	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. , 2015, , 589-611.		0
165	Medical Management of Serum Lipids and Coronary Heart Disease. Cardiovascular Medicine, 2015, , 39-55.	0.0	0
166	Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?. JAMA - Journal of the American Medical Association, 2015, 313, 1016.	3.8	15
167	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Cardiology Clinics, 2015, 33, 299-308.	0.9	3
168	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. Cardiology Clinics, 2015, 33, 309-323.	0.9	15

#	Article	IF	Citations
169	Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. Annual Review of Genomics and Human Genetics, 2015, 16, 327-350.	2.5	298
170	Dyslipidemia in Special Ethnic Populations. Cardiology Clinics, 2015, 33, 325-333.	0.9	39
171	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Cardiology Clinics, 2015, 33, 181-196.	0.9	24
172	Cardiovascular Risk Factors and Disease in Women. Medical Clinics of North America, 2015, 99, 535-552.	1.1	17
173	Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. Cardiovascular Endocrinology, 2015, 4, 11-16.	0.8	0
174	HDL â€“ Hope Dies Last?. Current Opinion in Lipidology, 2015, 26, 150-151.	1.2	0
175	Arterial Disorders. , 2015, , .		2
176	HDL re-examined. Current Opinion in Lipidology, 2015, 26, 127-132.	1.2	35
177	Apolipoprotein C-III. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 119-125.	1.2	87
178	Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. Cardiology and Therapy, 2015, 4, 25-38.	1.1	59
179	Learning by Experience. , 2015, , 331-337.		0
180	Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation. Trends in Molecular Medicine, 2015, 21, 245-255.	3.5	70
181	Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. Expert Opinion on Emerging Drugs, 2015, 20, 299-312.	1.0	6
182	Statins and Niacin: The End of Residual Risk Therapy?. , 2015, , 37-43.		2
183	Strategies for Improving Cardiovascular Health in Women With Diabetes Mellitus: a Review of the Evidence. Current Diabetes Reports, 2015, 15, 98.	1.7	2
184	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Current Cardiology Reports, 2015, 17, 104.	1.3	24
185	Nonstatin Therapies for Management of Dyslipidemia: A Review. Clinical Therapeutics, 2015, 37, 2153-2179.	1.1	39
186	Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study. Diabetologia, 2015, 58, 2774-2780.	2.9	39

#	Article	IF	Citations
187	Lipoprotein(a): Its relevance to the pediatric population. Journal of Clinical Lipidology, 2015, 9, S57-S66.	0.6	29
188	Nonstatin Low-Density Lipoproteinâ€“Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2269-2280.	1.1	58
189	Dyslipidemia in Obesity. , 2015, , 1-18.		1
190	Statin Intolerance: the Clinicianâ€™s Perspective. Current Atherosclerosis Reports, 2015, 17, 69.	2.0	43
191	Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?. American Journal of Medicine, 2015, 128, 1160-1161.	0.6	1
192	Adverse Drug Reaction reports for cardiometabolic drugs from subâ€Saharan Africa: a study in VigiBase. Tropical Medicine and International Health, 2015, 20, 797-806.	1.0	11
193	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1873-1875.	1.2	4
195	Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. Annals of Pharmacotherapy, 2015, 49, 1327-1335.	0.9	24
196	Reducing LDL with PCSK9 Inhibitors â€” The Clinical Benefit of Lipid Drugs. New England Journal of Medicine, 2015, 373, 1588-1591.	13.9	120
197	Fundamentals of Clinical Trials. , 2015, , .		603
198	Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2042-2047.	1.1	48
199	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1505-1515.	1.5	11
200	Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements. Alternative and Complementary Therapies, 2015, 21, 198-209.	0.1	1
201	Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia. Pharmacogenomics, 2015, 16, 1387-1397.	0.6	5
202	Safety and efficacy of ezetimibe: A meta-analysis. International Journal of Cardiology, 2015, 201, 247-252.	0.8	70
203	Mass spectrometry meets the challenge of understanding the complexity of the lipoproteome: recent findings regarding proteins involved in dyslipidemia and cardiovascular disease. Expert Review of Proteomics, 2015, 12, 519-532.	1.3	7
204	Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome. Evidence-Based Medicine, 2015, 20, 176-176.	0.6	1
205	Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. Clinical Infectious Diseases, 2015, 61, 840-849.	2.9	19

#	Article	IF	Citations
206	Antilipidemic Drug Therapy Today and in the Future. Handbook of Experimental Pharmacology, 2015, 233, 373-435.	0.9	5
207	HDL: Quality or quantity?. Atherosclerosis, 2015, 243, 121-123.	0.4	50
208	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascular Pharmacology, 2015, 72, 197-208.	1.0	14
209	Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?. Clinical Therapeutics, 2015, 37, 2716-2731.	1.1	27
210	PCSK9 Inhibition: Does Lipoprotein Size Matter?. Journal of the American Heart Association, 2015, 4, .	1.6	1
211	Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100â€“Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2686-2693.	1.1	45
212	Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of Medical Genetics, 2015, 52, 71-79.	1.5	52
213	2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk. Trends in Cardiovascular Medicine, 2015, 25, 340-347.	2.3	18
214	Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia. American Journal of Cardiology, 2015, 115, 178-182.	0.7	51
215	Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opinion on Pharmacotherapy, 2015, 16, 347-356.	0.9	6
216	The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology, 2015, 31, 605-612.	0.8	46
217	Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine, 2015, 43, 7-12.	0.2	1
218	Implications of reverse cholesterol transport: Recent studies. Clinica Chimica Acta, 2015, 439, 154-161.	0.5	30
219	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. Current Medical Research and Opinion, 2015, 31, 435-438.	0.9	4
220	With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes. Evidence-Based Medicine, 2015, 20, 12-12.	0.6	0
221	HDL functionality and crystal-based sterile inflammation in atherosclerosis. Clinica Chimica Acta, 2015, 439, 18-23.	0.5	16
222	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. , 0, , .		1
223	China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction. Chinese Medical Journal, 2016, 129, 72-80.	0.9	18

#	Article	IF	Citations
224	When is OTC niacin appropriate?. Pharmacy Today, 2016, 22, 20.	0.0	0
225	EDITORIAL: Repurposing Niacin as Antiplatelet Drug?. Current Clinical Pharmacology, 2016, 11, 2-3.	0.2	0
226	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
227	Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vascular Health and Risk Management, 2016, Volume 12, 421-433.	1.0	8
229	High-density lipoprotein: quantity or quality?. Journal of Thoracic Disease, 2016, 8, 2975-2977.	0.6	8
230	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. Cardiovascular Diagnosis and Therapy, 2016, 6, 282-303.	0.7	13
231	Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population. Archives of Medical Science, 2016, 6, 1188-1198.	0.4	3
232	Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 901-908.	0.5	27
233	Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation. Current Clinical Pharmacology, 2016, 11, 43-46.	0.2	1
234	Drugs That Affect Lipid Metabolism. Side Effects of Drugs Annual, 2016, 38, 469-477.	0.6	0
235	Disorders of Lipid Metabolism. , 2016, , 1660-1700.		7
236	Large Artery Occlusive Disease. , 0, , .		1
237	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. Korean Circulation Journal, 2016, 46, 135.	0.7	39
238	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
240	Management of Familial Hypercholesterolemia in Hong Kong. Journal of Atherosclerosis and Thrombosis, 2016, 23, 520-531.	0.9	10
241	Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients. PLoS ONE, 2016, 11, e0157507.	1.1	24
242	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World Journal of Cardiology, 2016, 8, 201.	0.5	47
243	What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 97-105.	1.2	9

#	Article	IF	Citations
244	Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?. Journal of Clinical Lipidology, 2016, 10, 1067-1072.	0.6	5
245	Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents. Journal of Cardiovascular Pharmacology, 2016, 68, 33-40.	0.8	55
246	Genetic insights into statin-associated diabetes risk. Current Opinion in Lipidology, 2016, 27, 125-130.	1.2	7
247	Lipoprotein(a) and risk of sudden cardiac death in middle-aged Finnish men: A new prospective cohort study. International Journal of Cardiology, 2016, 220, 718-725.	0.8	28
248	Digoxin reduces atherosclerosis in apolipoprotein Eâ€deficient mice. British Journal of Pharmacology, 2016, 173, 1517-1528.	2.7	44
249	Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm. Drugs, 2016, 76, 1081-1091.	4.9	17
250	Relation between plasma and brain lipids. Current Opinion in Lipidology, 2016, 27, 225-232.	1.2	22
251	Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in Health and Disease, 2016, 15, 116.	1.2	3
252	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. Circulation, 2016, 134, 1918-1930.	1.6	148
253	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	1.5	28
254	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm â€“ 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	1.1	405
258	The future of lipid guidelines. Current Opinion in Lipidology, 2016, 27, 585-591.	1.2	4
259	Niacin is still beneficial. Implications from an updated meta-regression analysis. Acta Cardiologica, 2016, 71, 463-472.	0.3	5
261	Trastornos del metabolismo lipÃ¤dico. Medicine, 2016, 12, 1059-1071.	0.0	0
262	Niacin: Time to Believe Outcomes Over Surrogate Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 343-344.	0.9	2
263	Managing dyslipidaemia in type 2 diabetes mellitus. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 431-444.	2.2	14
264	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of Clinical Lipidology, 2016, 10, 472-489.	0.6	219
265	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. Journal of Clinical Lipidology, 2016, 10, 519-527.e4.	0.6	42

#	Article	IF	Citations
266	Concentration of Smaller Highâ€Density Lipoprotein Particle (HDLâ€P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA). Journal of the American Heart Association, 2016, 5, .	1.6	34
267	HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1424-1430.	4.3	31
268	Monoclonal Antibodies for Lipid Management. Current Atherosclerosis Reports, 2016, 18, 39.	2.0	6
269	Modulating cholesterol efflux capacity to improve cardiovascular disease. Current Opinion in Lipidology, 2016, 27, 398-407.	1.2	39
270	Statin-Associated Side Effects. Journal of the American College of Cardiology, 2016, 67, 2395-2410.	1.2	495
271	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements, 2016, 18, C2-C12.	0.0	71
272	Viejos y nuevos hipolipemiantes. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 172-184.	0.0	0
273	Reply. Journal of the American College of Cardiology, 2016, 67, 120-121.	1.2	0
274	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology, 2016, 12, 467-484.	4.3	28
275	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Translational Research, 2016, 173, 30-57.	2.2	75
276	Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. American Journal of Kidney Diseases, 2016, 67, 965-977.	2.1	16
277	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2016, 68, 92-125.	1.2	371
279	Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy. Journal of Clinical Lipidology, 2016, 10, 116-123.	0.6	3
280	Statin combination therapy and cardiovascular risk reduction. Future Cardiology, 2016, 12, 289-315.	0.5	13
281	High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties. Molecular Metabolism, 2016, 5, 321-327.	3.0	16
282	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2016, 117, 1921-1927.	0.7	43
283	Positive correlation of serum HDL cholesterol with blood mercury concentration in metabolic syndrome Korean men (analysis of KNANES 2008â€“2010, 2013). Journal of Endocrinological Investigation, 2016, 39, 1031-1038.	1.8	6
284	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics, 2016, 48, 634-639.	9.4	214

#	Article	IF	Citations
285	Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation, 2017, 32, gfw042.	0.4	47
286	Niacin and olive oil promote skewing to the M2 phenotype in bone marrow-derived macrophages of mice with metabolic syndrome. Food and Function, 2016, 7, 2233-2238.	2.1	14
287	Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism: Clinical and Experimental, 2016, 65, 1109-1123.	1.5	363
288	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 206-212.	0.9	71
289	Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitusâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 787-791.	1.1	33
290	Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Review of Cardiovascular Therapy, 2016, 14, 953-962.	0.6	26
291	Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 2016, 183, 875-883.	1.6	49
292	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.4	1,189
293	The effect of hematocrit and hemoglobin on the risk of ischemic heart disease: A Mendelian randomization study. Preventive Medicine, 2016, 91, 351-355.	1.6	13
294	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism: Clinical and Experimental, 2016, 65, 1664-1678.	1.5	85
295	HDL metrics, letâ€™s call the number thing off?. Atherosclerosis, 2016, 251, 525-527.	0.4	6
296	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289.	3.8	974
297	Ischemic stroke in a young adult with extremely elevated lipoprotein(a): A case report and review of literature. Journal of Clinical Lipidology, 2016, 10, 1266-1271.	0.6	6
298	Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. Journal of Clinical Lipidology, 2016, 10, 1137-1144.e3.	0.6	26
299	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Current Hypertension Reports, 2016, 18, 76.	1.5	51
300	Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma. Medicina ClÃnica (English Edition), 2016, 146, 117-120.	0.1	1
301	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology, 2016, 225, 184-196.	0.8	155
302	Hypertriglyceridemia: the importance of identifying patients at risk. Postgraduate Medicine, 2016, 128, 848-858.	0.9	28

#	Article	IF	Citations
303	A review of PCSK9 inhibition and its effects beyond LDL receptors. Journal of Clinical Lipidology, 2016, 10, 1073-1080.	0.6	39
304	Familial Hypercholesterolemia: Advances in Recognition and Therapy. Progress in Cardiovascular Diseases, 2016, 59, 125-134.	1.6	13
305	Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opinion on Drug Safety, 2016, 15, 1301-1312.	1.0	13
306	Advances in Lipid Therapy: The Role of Lipid Treatment in Women in Primary Prevention. Progress in Cardiovascular Diseases, 2016, 59, 178-189.	1.6	6
307	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2016, 35, 1295-1302.	0.3	12
308	Statin Intolerance: A Literature Review and Management Strategies. Progress in Cardiovascular Diseases, 2016, 59, 153-164.	1.6	60
309	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Nonâ€Familial Hypercholesterolemia. Progress in Cardiovascular Diseases, 2016, 59, 165-171.	1.6	11
310	Association Between Very Low Levels of Highâ€Density Lipoprotein Cholesterol and Longâ€term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the <scp>TRILOGY ACS</scp> Trial. Clinical Cardiology, 2016, 39, 329-337.	0.7	7
311	Niacin promotes revascularization and recovery of limb function in dietâ€induced obese mice with peripheral ischemia. Pharmacology Research and Perspectives, 2016, 4, e00233.	1.1	8
312	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	1.0	2,393
313	Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. Clinical Infectious Diseases, 2016, 63, S39-S45.	2.9	4
314	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal, 2016, 180, 22-28.	1.2	25
315	Nicotinic acid and derivatives. , 2016, , 157-162.		0
316	Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy, 2016, 14, 1263-1271.	0.6	8
318	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation. Circulation: Cardiovascular Genetics, 2016, 9, 340-348.	5.1	59
319	Determining When to Add Nonstatin Therapy. Journal of the American College of Cardiology, 2016, 68, 2412-2421.	1.2	125
320	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, The, 2016, 388, 2532-2561.	6.3	1,399
321	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775

#	Article	IF	Citations
322	Refocusing the AIM on HDL in the metabolic syndrome. Atherosclerosis, 2016, 251, 531-533.	0.4	3
323	Targeting ApoC-III to Reduce Coronary Disease Risk. Current Atherosclerosis Reports, 2016, 18, 54.	2.0	31
324	Environment-wide association study to identify factors associated with hematocrit: evidence from the Guangzhou Biobank Cohort Study. Annals of Epidemiology, 2016, 26, 638-642.e2.	0.9	5
325	Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Current Cardiology Reports, 2016, 18, 133.	1.3	4
326	Rationale and strategies for formulation development of oral fixed dose combination drug products. Journal of Pharmaceutical Investigation, 2016, 46, 615-631.	2.7	18
327	Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. Current Atherosclerosis Reports, 2016, 18, 69.	2.0	9
328	HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics. Current Atherosclerosis Reports, 2016, 18, 71.	2.0	9
329	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 348-354.	0.9	8
330	Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. Current Cardiology Reports, 2016, 18, 114.	1.3	3
331	Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta Pharmaceutica, 2016, 66, 449-469.	0.9	21
332	High-Density Lipoprotein Cholesterol andÂCause-Specific Mortality in IndividualsÂWithout Previous Cardiovascular Conditions. Journal of the American College of Cardiology, 2016, 68, 2073-2083.	1.2	253
333	Mendelian randomization analysis of a timeâ€varying exposure for binary disease outcomes using functional data analysis methods. Genetic Epidemiology, 2016, 40, 744-755.	0.6	13
334	Low-density lipoprotein cholesterol goals: still not in patients' best interest: TableÂ1. Evidence-Based Medicine, 2016, 21, 128-133.	0.6	1
335	The role of HDL in plaque stabilization and regression. Coronary Artery Disease, 2016, 27, 592-603.	0.3	16
336	HDL infusion for the management of atherosclerosis. Current Opinion in Lipidology, 2016, 27, 592-596.	1.2	12
337	Icosabutate, a More Potent Form of Omega 3 Fatty Acids, Shows Promise in Lowering Triglycerides. Cardiology, 2016, 135, 1-2.	0.6	1
338	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. Wiener Klinische Wochenschrift, 2016, 128, 216-228.	1.0	8
339	Management of Moderate Hypertriglyceridemia in Childhood and Adolescence. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	1

#	Article	IF	Citations
340	HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis, 2016, 251, 381-388.	0.4	51
341	Where to now in cardiovascular disease prevention. Atherosclerosis, 2016, 251, 483-489.	0.4	2
342	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes, 2016, 65, 1767-1778.	0.3	155
345	Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. American Journal of Medicine, 2016, 129, 753.e13-753.e22.	0.6	16
346	Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. Journal of Clinical Lipidology, 2016, 10, 314-322.	0.6	4
347	Should we welcome food industry funding of public health research?. BMJ, The, 2016, 353, i2161.	3.0	17
348	Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a). Annals of Pharmacotherapy, 2016, 50, 609-615.	0.9	7
349	My Approach to the Patient With Familial Hypercholesterolemia. Mayo Clinic Proceedings, 2016, 91, 770-786.	1.4	35
350	Enhancing clinical evidence by proactively building quality into clinical trials. Clinical Trials, 2016, 13, 439-444.	0.7	45
351	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
352	Current therapies for lowering lipoprotein (a). Journal of Lipid Research, 2016, 57, 1612-1618.	2.0	77
353	Reduction in Total Cardiovascular Events WithÂEzetimibe/Simvastatin Post-Acute Coronary Syndrome. Journal of the American College of Cardiology, 2016, 67, 353-361.	1.2	173
354	Niacin: old habits die hard. Heart, 2016, 102, 170-171.	1.2	1
355	Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism: Clinical and Experimental, 2016, 65, 609-622.	1.5	14
356	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology, 2016, 32, S35-S65.	0.8	194
357	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy, 2016, 17, 275-281.	0.9	9
358	The unresolved mystery of high-density lipoprotein: time for a paradigm shift?. Translational Research, 2016, 173, 1-6.	2.2	2
359	A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 23-29.	1.4	61

#	Article	IF	Citations
360	Dyslipidemia Part 2. Vascular and Endovascular Surgery, 2016, 50, 119-135.	0.3	4
361	New Era of Lipid-Lowering Drugs. Pharmacological Reviews, 2016, 68, 458-475.	7.1	45
362	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 586-590.	1.1	15
363	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. Clinical Pharmacology and Therapeutics, 2016, 99, 59-71.	2.3	10
364	Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. Journal of Clinical Lipidology, 2016, 10, 905-914.	0.6	54
366	Lipid Management in Human Immunodeficiency Virus. Endocrinology and Metabolism Clinics of North America, 2016, 45, 141-169.	1.2	8
367	Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Endocrinology and Metabolism Clinics of North America, 2016, 45, 171-184.	1.2	1
368	Dyslipidemia in Special Ethnic Populations. Endocrinology and Metabolism Clinics of North America, 2016, 45, 205-216.	1.2	13
369	Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research, 2016, 106, 37-50.	3.1	66
370	Niacin Alternatives for Dyslipidemia: Foolâ€™s Gold or Gold Mine? Part I: Alternative Niacin Regimens. Current Atherosclerosis Reports, 2016, 18, 11.	2.0	11
371	High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis, 2016, 246, 229-235.	0.4	56
372	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Endocrinology and Metabolism Clinics of North America, 2016, 45, 17-37.	1.2	22
373	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. Endocrinology and Metabolism Clinics of North America, 2016, 45, 185-204.	1.2	20
374	From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749.	2.0	180
375	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology, 2016, 10, 240-264.	0.6	3
376	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. Circulation Research, 2016, 118, 547-563.	2.0	701
377	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Current Neurology and Neuroscience Reports, 2016, 16, 24.	2.0	12
378	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. Expert Opinion on Therapeutic Targets, 2016, 20, 907-921.	1.5	11

#	Article	IF	Citations
379	Icosapent ethyl in hypertriglyceridaemia: a guide to its use. Drugs and Therapy Perspectives, 2016, 32, 91-97.	0.3	0
380	Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis, 2016, 246, 121-129.	0.4	3
381	Dyslipidemia in Obesity. , 2016, , 525-540.		4
382	Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 285-294.	1.1	17
383	Lipoprotein apheresis to treat elevated lipoprotein (a). Journal of Lipid Research, 2016, 57, 1751-1757.	2.0	78
384	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 804-814.	1.8	36
385	Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovascular Drugs and Therapy, 2016, 30, 87-100.	1.3	165
386	Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 817-824.	1.1	61
387	Slippery Slope of Triglycerides. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 97-99.	0.9	4
388	Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascular Pharmacology, 2016, 81, 22-30.	1.0	21
389	Niacin Alternatives for Dyslipidemia: Foolâ€™s Gold or Gold Mine? Part II: Novel Niacin Mimetics. Current Atherosclerosis Reports, 2016, 18, 17.	2.0	23
390	Cardiovascular risk reduction: the future of cholesterol lowering drugs. Current Opinion in Pharmacology, 2016, 27, 62-69.	1.7	7
391	The High-Density Lipoprotein Puzzle. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 777-782.	1.1	42
392	Omega-3 supplements and cardiovascular disease. Re: Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr Med Res Opin 2015: 32(2);301â€“311. Current Medical Research and Opinion, 2016, 32, 583-584.	0.9	1
393	Management of residual risk after statin therapy. Atherosclerosis, 2016, 245, 161-170.	0.4	71
394	HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. Current Atherosclerosis Reports, 2016, 18, 2.	2.0	46
395	Drug and Gene Delivery using Sonoporation for Cardiovascular Disease. Advances in Experimental Medicine and Biology, 2016, 880, 331-338.	0.8	18
396	Protective features of peripheral monocytes/macrophages in stroke. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 329-338.	1.8	71

#	Article	IF	Citations
397	Metabolic syndrome update. Trends in Cardiovascular Medicine, 2016, 26, 364-373.	2.3	576
398	Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart, 2016, 102, 198-203.	1.2	56
399	Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature Reviews Cardiology, 2016, 13, 48-60.	6.1	547
400	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American Journal of Cardiovascular Drugs, 2016, 16, 55-65.	1.0	82
401	Targeting inflammation in metabolic syndrome. Translational Research, 2016, 167, 257-280.	2.2	189
402	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, 2016, 37, 747-754.	1.0	62
403	Treatment of Hypercholesterolemia in 2015. American Journal of Therapeutics, 2017, 24, e121-e129.	0.5	2
404	Niacin Promotes Cardiac Healing after Myocardial Infarction through Activation of the Myeloid Prostaglandin D₂ Receptor Subtype 1. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 435-444.	1.3	18
405	Statin-associated muscle symptomsâ€"Managing the highly intolerant. Journal of Clinical Lipidology, 2017, 11, 24-33.	0.6	44
407	High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis, 2017, 259, 104-113.	0.4	48
408	The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S175-S179.	1.8	17
409	Pre-heparin lipoprotein lipase mass as a potential mediator in the association between adiponectin and HDL-cholesterol in type 2 diabetes. Journal of Clinical and Translational Endocrinology, 2017, 7, 7-11.	1.0	3
410	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 7.	1.3	42
411	Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. Journal of Lipid Research, 2017, 58, 783-797.	2.0	5
412	Omega-3 Fatty Acid Therapy: The Tide Turns for a Fish Story. Mayo Clinic Proceedings, 2017, 92, 1-3.	1.4	21
413	CETP. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 396-400.	1.1	27
414	Evidence-based goals in LDL-C reduction. Clinical Research in Cardiology, 2017, 106, 237-248.	1.5	69
415	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 19.	1.3	19

#	Article	IF	Citations
416	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)â€"A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American Heart Journal, 2017, 187, 182-190.	1.2	66
417	Heat shock protein 27â€"derived atheroprotection involves reverse cholesterol transport that is dependent on GMâ€CSF to maintain ABCA1 and ABCG1 expression in ApoE ^{â^'} / ^{â^'} mice.. FASEB Journal, 2017, 31, 2364-2379.	0.2	24
418	2017 Taiwan lipid guidelines for high risk patients. Journal of the Formosan Medical Association, 2017, 116, 217-248.	0.8	123
419	Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors: a systematic review and metaâ€analysis. Journal of Human Nutrition and Dietetics, 2017, 30, 621-633.	1.3	75
420	Plant sterol enriched functional food and atherosclerosis. British Journal of Pharmacology, 2017, 174, 1281-1289.	2.7	45
421	Effects of curcumin on HDL functionality. Pharmacological Research, 2017, 119, 208-218.	3.1	157
422	What role for lipoprotein(a) in clinical practice?. Lancet Diabetes and Endocrinology,the, 2017, 5, 487-489.	5.5	3
423	Editorial commentary: Importance of triglycerides. Trends in Cardiovascular Medicine, 2017, 27, 433-434.	2.3	0
424	PCSK9 as a therapeutic target for cardiovascular disease. Experimental and Therapeutic Medicine, 2017, 13, 810-814.	0.8	15
425	Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. Scientific Reports, 2017, 7, 46642.	1.6	30
426	Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?. Current Cardiology Reports, 2017, 19, 47.	1.3	23
427	Increasing HDL-C levels with medication. Current Opinion in Lipidology, 2017, 28, 361-366.	1.2	12
428	A high-power and fast charging Li-ion battery with outstanding cycle-life. Scientific Reports, 2017, 7, 1104.	1.6	37
429	Vitamin supplements in type 2 diabetes mellitus management: A review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S589-S595.	1.8	17
430	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Current Atherosclerosis Reports, 2017, 19, 29.	2.0	11
431	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	1.1	766
432	The Role of Emerging Risk Factors in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 28.	2.0	43
433	How important are triglycerides as risk factors?. Journal of Cardiovascular Medicine, 2017, 18, e7-e12.	0.6	1

#	Article	IF	Citations
434	The first Late Triassic Chinese triadophlebiomorphan (Insecta: Odonatoptera): biogeographic implications. Scientific Reports, 2017, 7, 1476.	1.6	5
435	Rediscovering scavenger receptor type BI. Current Opinion in Lipidology, 2017, 28, 255-260.	1.2	20
436	Xinxuekang Regulates Reverse Cholesterol Transport by Improving High-density Lipoprotein Synthesis, Maturation, and Catabolism. Journal of Cardiovascular Pharmacology, 2017, 70, 110-118.	0.8	8
437	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atherosclerosis Supplements, 2017, 26, 16-24.	1.2	24
438	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. American Journal of Cardiovascular Drugs, 2017, 17, 447-452.	1.0	2
439	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. Circulation, 2017, 135, 2494-2504.	1.6	180
440	Human genetic insights into lipoproteins and risk of cardiometabolic disease. Current Opinion in Lipidology, 2017, 28, 113-119.	1.2	12
441	Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk. JAMA Cardiology, 2017, 2, 218.	3.0	1
442	Extendedâ€•release niacin increases antiâ€•apolipoprotein Aâ€• antibodies that block the antioxidant effect of highâ€•density lipoproteinâ€“cholesterol: the EXPLORE clinical trial. British Journal of Clinical Pharmacology, 2017, 83, 1002-1010.	1.1	20
443	Pitavastatin and HDL: Effects on plasma levels and function(s). Atherosclerosis Supplements, 2017, 27, e1-e9.	1.2	21
444	Niacin for primary and secondary prevention of cardiovascular events. The Cochrane Library, 2017, 2017, CD009744.	1.5	43
445	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. Journal of Clinical Lipidology, 2017, 11, 929-937.	0.6	9
446	Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys. Journal of Lipid Research, 2017, 58, 1282-1291.	2.0	13
447	Lipoprotein(a): A Lipoprotein Whose Time Has Come. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 48.	0.4	12
448	Dyslipidemia management update. Current Opinion in Pharmacology, 2017, 33, 47-55.	1.7	41
449	Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders. Expert Opinion on Orphan Drugs, 2017, 5, 411-420.	0.5	1
450	Improving public health by improving clinical trial guidelines and their application. European Heart Journal, 2017, 38, 1632-1637.	1.0	19
451	Genetic coding variants in the niacin receptor, hydroxylâ€“carboxylic acid receptor 2, and response to niacin therapy. Pharmacogenetics and Genomics, 2017, 27, 285-293.	0.7	10

#	Article	IF	Citations
452	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150â€“499 mg/dL). Journal of Clinical Lipidology, 2017, 11, 872-879.	0.6	9
453	Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing. American Journal of Health-System Pharmacy, 2017, 74, 898-903.	0.5	2
454	Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases. Current Opinion in Lipidology, 2017, 28, 337-346.	1.2	9
455	Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complementary Therapies in Medicine, 2017, 33, 1-5.	1.3	160
456	Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. Atherosclerosis Supplements, 2017, 30, 174-179.	1.2	21
457	Lipoprotein(a): the revenant. European Heart Journal, 2017, 38, 1553-1560.	1.0	133
458	Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990â€“2011. Journal of the American Heart Association, 2017, 6, .	1.6	37
459	Current status of lipid management in acute coronary syndrome. Journal of Cardiology, 2017, 70, 101-106.	0.8	16
460	Triglycerides: A reappraisal. Trends in Cardiovascular Medicine, 2017, 27, 428-432.	2.3	12
461	Chronic kidney disease and dyslipidaemia. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2017, 29, 22-35.	0.1	6
462	Association between High-density-lipoprotein-cholesterol Levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis. Scientific Reports, 2017, 7, 573.	1.6	12
463	Dyslipidemia in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 27-32.	0.8	41
464	Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids. Endocrine Practice, 2017, 23, 100-112.	1.1	39
465	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm â€“ 2017 Executive Summary. Endocrine Practice, 2017, 23, 207-238.	1.1	362
466	HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology, 2017, 106, 663-675.	1.5	186
467	Rationale and design of <scp>REDUCEâ€IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€“Intervention Trial. Clinical Cardiology, 2017, 40, 138-148.	0.7	154
468	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. Nature Reviews Cardiology, 2017, 14, 387-400.	6.1	66
469	Dyslipidemia in patients with chronic kidney disease. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 29-40.	2.6	139

#	Article	IF	Citations
470	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiology, 2017, 2, 370.	3.0	136
471	The Changing Face of HDL and the Best Way to Measure It. Clinical Chemistry, 2017, 63, 196-210.	1.5	86
472	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs, 2017, 22, 1-26.	1.0	45
473	Statins, Ezetimibe, and Proprotein Convertase Subtilisinâ€“Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. American Journal of Cardiology, 2017, 119, 565-571.	0.7	14
474	Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 316-327.	1.1	30
475	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. American Journal of Cardiovascular Drugs, 2017, 17, 169-181.	1.0	19
476	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Advances in Therapy, 2017, 34, 300-323.	1.3	37
477	Triglyceride-lowering trials. Current Opinion in Lipidology, 2017, 28, 477-487.	1.2	12
478	Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?. Postgraduate Medicine, 2017, 129, 822-827.	0.9	22
479	Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Current Atherosclerosis Reports, 2017, 19, 43.	2.0	7
480	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Current Diabetes Reports, 2017, 17, 112.	1.7	22
481	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	13.9	780
482	Association of high-density lipoprotein cholesterol concentration with different types of stroke and coronary heart disease: The Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis, 2017, 265, 147-154.	0.4	43
483	Niacin and heart disease prevention: Engraving its tombstone is a mistake. Journal of Clinical Lipidology, 2017, 11, 1309-1317.	0.6	33
484	Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage. Scientific Reports, 2017, 7, 9489.	1.6	11
485	High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. Atherosclerosis, 2017, 265, 110-116.	0.4	15
486	2017 Focused Update of the 2016ÂACCÂExpert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering inÂthe Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2017, 70, 1785-1822.	1.2	313
487	Recomendaciones prÃ¡cticas para el manejo del riesgo cardiovascular asociado a la dislipemia aterogÃ©nica, con especial atenciÃ³n al riesgo residual. AdaptaciÃ³n espaÃ±ola de un Consenso Europeo de Expertos. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2017, 29, 168-177.	0.4	8

#	Article	IF	Citations
488	Treatment of Cholesterol in 2017. JAMA - Journal of the American Medical Association, 2017, 318, 417.	3.8	29
490	The Reply. American Journal of Medicine, 2017, 130, e349.	0.6	0
491	Lipoprotein(a)-apheresis in the light of new drug developments. Atherosclerosis Supplements, 2017, 30, 38-43.	1.2	12
492	Computed tomography angiography defined vulnerable plaque in a patient with low high-density lipoprotein cholesterol and subsequent myocardial infarction. Coronary Artery Disease, 2017, 28, 712-714.	0.3	0
493	Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study. Cardiovascular Drugs and Therapy, 2017, 31, 269-279.	1.3	9
494	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2017, 29, 168-177.	0.1	1
495	Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. Journal of Clinical Lipidology, 2017, 11, 1177-1180.	0.6	13
496	Discovery of pentacyclic triterpene 3Î²-ester derivatives as a new class of cholesterol ester transfer protein inhibitors. European Journal of Medicinal Chemistry, 2017, 139, 201-213.	2.6	8
497	Obesity is associated with an altered HDL subspecies profile among adolescents with metabolic disease. Journal of Lipid Research, 2017, 58, 1916-1923.	2.0	20
499	Î² 3 -Adrenergic receptor regulates hepatic apolipoprotein A-I gene expression. Journal of Clinical Lipidology, 2017, 11, 1168-1176.	0.6	3
500	Time to ditch HDL-C as a measure of HDL function?. Current Opinion in Lipidology, 2017, 28, 414-418.	1.2	40
502	HDL functionality in type 1 diabetes. Atherosclerosis, 2017, 267, 99-109.	0.4	50
503	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. Current Cardiology Reports, 2017, 19, 132.	1.3	85
504	Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a). Current Pharmacology Reports, 2017, 3, 458-468.	1.5	3
505	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. Journal of Clinical Lipidology, 2017, 11, 1192-1200.e3.	0.6	9
506	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2017, 18, 1243-1260.	0.9	35
507	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Current Cardiology Reports, 2017, 19, 61.	1.3	12
508	Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology, 2017, 18, 147.	0.8	12

#	Article	IF	Citations
509	Effect of ezetimibe add-on therapy over 52Âweeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids in Health and Disease, 2017, 16, 122.	1.2	16
510	The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention. Current Opinion in Cardiology, 2017, 32, 633-641.	0.8	2
511	Role of Niacin in Current Clinical Practice: A Systematic Review. American Journal of Medicine, 2017, 130, 173-187.	0.6	66
512	Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study. American Heart Journal, 2017, 183, 74-84.	1.2	19
513	Plaque imaging to refine indications for emerging lipid-lowering drugs. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 58-67.	1.4	26
515	Prognostic significance of major lipids in patients with acute ischemic stroke. Metabolic Brain Disease, 2017, 32, 395-400.	1.4	25
516	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. American Journal of Cardiovascular Drugs, 2017, 17, 83-95.	1.0	11
517	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. Canadian Journal of Cardiology, 2017, 33, 325-333.	0.8	41
518	Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After IntensiveÂStatinÂTreatment. Journal of the American College of Cardiology, 2017, 69, 628-640.	1.2	56
519	Cholesteryl Ester Transfer Protein Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 99-104.	1.0	11
520	Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clinical Nutrition, 2017, 36, 1136-1142.	2.3	15
521	Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors. European Journal of Medicinal Chemistry, 2017, 126, 143-153.	2.6	16
522	Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology, 2017, 10, 187-200.	1.3	23
523	Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke. Stroke, 2017, 48, 36-42.	1.0	20
524	Statins and the cholesterol mortality paradox. Scottish Medical Journal, 2017, 62, 19-23.	0.7	10
525	Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S]. Journal of Lipid Research, 2017, 58, 31-41.	2.0	14
526	HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization. International Journal of Epidemiology, 2017, 46, 1891-1902.	0.9	73
527	Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	1.6	23

#	Article	IF	Citations
528	Managing hypertriglyceridemia. Nurse Practitioner, 2017, 42, 3-9.	0.2	1
529	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 2017, 70, 1290-1301.	1.2	162
530	Risk Factors. , 2017, , 383-392.		0
531	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70
532	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. Current Cardiology Reviews, 2017, 13, 168-182.	0.6	9
533	Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. PLoS ONE, 2017, 12, e0182217.	1.1	22
534	High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis. Lipids in Health and Disease, 2017, 16, 212.	1.2	63
535	Pathophysiology of Diabetic Dyslipidaemia. Current Vascular Pharmacology, 2017, 15, 566-575.	0.8	31
536	Statin Intolerance: Diagnosis and Management. Indian Journal of Cardiovascular Disease in Women WINCARS, 2017, 02, 014-020.	0.1	0
537	Cholesterol and Lipids. , 2017, , 9-21.		0
538	New European Society of Cardiology/European Atherosclerosis Society Guideline for the Management of Dyslipidemia. Journal of Lipid and Atherosclerosis, 2017, 6, 8.	1.1	0
539	Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment. journal of applied laboratory medicine, The, 2017, 2, 186-200.	0.6	34
540	ADVERSE EFFECTS AND SIDE EFFECTS ON VITAMIN THERAPY: A REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 19.	0.3	4
541	Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease. Journal of Thoracic Disease, 2017, 9, 1822-1825.	0.6	1
542	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovascular Diagnosis and Therapy, 2017, 7, 45-51.	0.7	49
543	Treating Dyslipidemia in Type 2 Diabetes. Cardiology Clinics, 2018, 36, 233-239.	0.9	11
544	High-Density Lipoprotein Infusions. Cardiology Clinics, 2018, 36, 311-315.	0.9	3
545	Low Levels of High-Density Lipoprotein Cholesterol Are Linked to Impaired Clopidogrel-Mediated Platelet Inhibition. Angiology, 2018, 69, 786-794.	0.8	6

#	Article	IF	Citations
546	Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes and Metabolism, 2018, 44, 508-513.	1.4	40
547	Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. Journal of Clinical Lipidology, 2018, 12, 348-355.e2.	0.6	41
548	Low-density lipoprotein cholesterol and risk of type 2 diabetes: The Isfahan diabetes prevention study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 715-719.	1.8	11
549	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
550	Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. European Heart Journal, 2018, 39, 2172-2178.	1.0	53
551	High-Density Lipoproteins. Cardiology Clinics, 2018, 36, 317-327.	0.9	14
552	Preventive Cardiology. , 2018, , 269-289.		0
553	Dyslipidemia. Canadian Journal of Diabetes, 2018, 42, S178-S185.	0.4	50
554	Back to the future: the urgent need to re-introduce streamlined trials. European Heart Journal Supplements, 2018, 20, C14-C17.	0.0	5
555	Prevention and management of statin adverse effects: A practical approach for pharmacists. Canadian Pharmacists Journal, 2018, 151, 179-188.	0.4	19
556	High-density lipoprotein cholesterol and causes of death in chronic kidney disease. Journal of Clinical Lipidology, 2018, 12, 1061-1071.e7.	0.6	15
557	The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 301-308.	1.0	6
558	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. Canadian Journal of Cardiology, 2018, 34, 532-535.	0.8	1
559	Therapeutic Lowering of Lipoprotein(a). Circulation Genomic and Precision Medicine, 2018, 11, e002052.	1.6	6
560	Disconnect Between Genes Associated With Ischemic Heart Disease and Targets of Ischemic Heart Disease Treatments. EBioMedicine, 2018, 28, 311-315.	2.7	15
561	Inhibition of hepatic apolipoprotein A-I gene expression by histamine. European Journal of Pharmacology, 2018, 823, 49-57.	1.7	7
562	From High-Density Lipoprotein Cholesterol to Measurements of Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 487-499.	1.1	94
563	Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200â€“499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clinical Cardiology, 2018, 41, 13-19.	0.7	63

#	Article	IF	Citations
564	The role of lipoprotein (a) in chronic kidney disease. Journal of Lipid Research, 2018, 59, 577-585.	2.0	77
565	Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochemical and Biophysical Research Communications, 2018, 496, 335-338.	1.0	35
566	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. Postgraduate Medicine, 2018, 130, 287-298.	0.9	8
567	Lipid-lowering treatment in peripheral artery disease. Current Opinion in Pharmacology, 2018, 39, 19-26.	1.7	19
568	The pharmacological management of metabolic syndrome. Expert Review of Clinical Pharmacology, 2018, 11, 397-410.	1.3	80
569	Evolving Role of Nonâ€Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy, 2018, 38, 164-171.	1.2	7
570	Managing Dyslipidemia in Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2018, 47, 153-173.	1.2	24
571	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Canadian Journal of Cardiology, 2018, 34, 595-604.	0.8	56
572	High-Density Lipoprotein Cholesterol and Mortality. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 669-672.	1.1	85
573	Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology, 2018, 11, 259-278.	1.3	7
574	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. Atherosclerosis, 2018, 269, 92-99.	0.4	11
575	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 119-127.	1.4	17
576	Pharmacogenomics of blood lipid regulation. Pharmacogenomics, 2018, 19, 651-665.	0.6	3
577	Antibodies against HDL Components in Ischaemic Stroke and Coronary Artery Disease. Thrombosis and Haemostasis, 2018, 118, 1088-1100.	1.8	13
578	Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. Atherosclerosis, 2018, 274, 16-22.	0.4	30
579	Causal Effect of Lipids and Lipoproteins on Atherosclerosis. Cardiology Clinics, 2018, 36, 203-211.	0.9	26
580	Overexpressing human GPR109A leads to pronounced reduction in plasma triglyceride levels in BAC transgenic rats. Atherosclerosis, 2018, 272, 182-192.	0.4	5
581	An update on trials of novel lipid-lowering drugs. Current Opinion in Cardiology, 2018, 33, 416-422.	0.8	5

#	Article	IF	Citations
582	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. Critical Reviews in Food Science and Nutrition, 2018, 58, 958-971.	5.4	27
583	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes, Obesity and Metabolism, 2018, 20, 270-282.	2.2	22
584	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2018, 103, 712-721.	2.3	30
585	Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target?. Journal of Cardiology, 2018, 71, 8-9.	0.8	13
586	Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. Clinical Chemistry, 2018, 64, 219-230.	1.5	79
587	HDL biogenesis revisited: how desmocollin-1 could sabotage reverse cholesterol transport in the arterial wall. European Heart Journal, 2018, 39, 1203-1206.	1.0	1
589	Should an LDL-Cholesterol Targetâ€“Based Approach Be Readopted?. Annals of Pharmacotherapy, 2018, 52, 175-184.	0.9	6
590	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm. JAMA Cardiology, 2018, 3, 26.	3.0	75
591	9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2018. Diabetes Care, 2018, 41, S86-S104.	4.3	461
592	Safety assessment of niacin in the US Food and Drug Administration's miniâ€sentinel system. Pharmacoepidemiology and Drug Safety, 2018, 27, 30-37.	0.9	10
593	Dynamic changes of the composition of plasma <scp>HDL</scp> particles in patients with cardiac disease: Spotlight on sphingosineâ€1â€phosphate/serum amyloid A ratio. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 319-325.	0.9	3
594	Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1. Journal of Clinical Lipidology, 2018, 12, 116-121.	0.6	23
595	The Role of Metabolite-Sensing G Protein-Coupled Receptors in Inflammation and Metabolic Disease. Antioxidants and Redox Signaling, 2018, 29, 237-256.	2.5	13
596	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nature Reviews Cardiology, 2018, 15, 9-19.	6.1	105
598	Lipid Measurements. , 2018, , 88-97.		0
599	Primary Prevention of Atherosclerotic Cardiovascular Disease. , 2018, , 433-458.		0
600	The pleiotropic vasoprotective functions of high density lipoproteins (HDL). Journal of Biomedical Research, 2018, 32, .	0.7	23
601	Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases. Health Evaluation and Promotion, 2018, 45, 755-769.	0.0	0

#	Article	IF	Citations
602	High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs in Context, 2018, 7, 1-9.	1.0	129
603	Severe hypertriglyceridemia. Clinical characteristics and therapeutic management. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 217-223.	0.1	0
604	Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids in Health and Disease, 2018, 17, 265.	1.2	18
605	Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. Journal of the American Heart Association, 2018, 7, e03488.	1.6	8
606	USF1 deficiency alleviates inflammation, enhances cholesterol efflux and prevents cholesterol accumulation in macrophages. Lipids in Health and Disease, 2018, 17, 285.	1.2	16
607	Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. Drugs in Context, 2018, 7, 1-7.	1.0	14
608	Characterization of a peptide containing the major heparin binding domain of human hepatic lipase. Journal of Peptide Science, 2018, 24, e3123.	0.8	2
609	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?. Current Cardiology Reports, 2018, 20, 113.	1.3	19
610	Cholesteryl ester transfer protein: An enigmatic pharmacology â€“ Antagonists and agonists. Atherosclerosis, 2018, 278, 286-298.	0.4	25
611	Lipoprotein(a)â€”It Is Risky, but What Do We Do About It?. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	1
612	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
613	Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. Current Cardiology Reports, 2018, 20, 125.	1.3	15
614	Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy (Basel, Switzerland), 2018, 6, 10.	0.6	59
615	Genetics of Coronary Atherosclerosis. , 2018, , 33-44.		0
616	Translating Evidence of HDL and Plaque Regression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1961-1968.	1.1	25
617	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Expert Opinion on Investigational Drugs, 2018, 27, 997-1005.	1.9	18
618	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
619	Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation Genomic and Precision Medicine, 2018, 11, e001696.	1.6	65

#	Article	IF	Citations
620	Beyond Statins: Who and When to Prescribe?. Current Diabetes Reports, 2018, 18, 126.	1.7	4
621	Simvastatin Treatment Protects Myocardium in Noncoronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting. Journal of Cardiovascular Pharmacology, 2018, 72, 176-185.	0.8	14
622	Cardiovascular Effects and Benefits of Exercise. Frontiers in Cardiovascular Medicine, 2018, 5, 135.	1.1	386
623	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current Diabetes Reports, 2018, 18, 138.	1.7	4
624	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. Journal of Atherosclerosis and Thrombosis, 2018, 25, 846-984.	0.9	541
625	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Realâ€World Administrative Claims Analysis of Statinâ€Treated Patients With High Residual Cardiovascular Risk. Journal of the American Heart Association, 2018, 7, e008740.	1.6	81
626	High-density lipoprotein (HDL) cholesterol â€“ more complicated than we think?. Annals of Agricultural and Environmental Medicine, 2018, 25, 517-526.	0.5	13
627	Primary and Secondary Prevention of Cardiovascular Disease. , 2018, , 63-76.		0
628	Biologic bases of residual risk of cardiovascular events: A flawed concept. European Journal of Preventive Cardiology, 2018, 25, 1831-1835.	0.8	8
629	Top 20 POEMs of the Past 20 Years: A Survey of Practice-Changing Research for Family Physicians. Annals of Family Medicine, 2018, 16, 436-439.	0.9	3
630	Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. Current Diabetes Reports, 2018, 18, 92.	1.7	20
631	Diabetes alters the association between high-density lipoprotein subfractions and carotid intima-media thickness: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetes and Vascular Disease Research, 2018, 15, 541-547.	0.9	6
632	Supplemental Vitamins and Minerals forÂCVD Prevention and Treatment. Journal of the American College of Cardiology, 2018, 71, 2570-2584.	1.2	184
633	Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine and Pharmacotherapy, 2018, 103, 1231-1237.	2.5	66
634	Acute pancreatitis secondary to oral contraceptive-induced hypertriglyceridemia: a case report. Gynecological Endocrinology, 2018, 34, 930-932.	0.7	4
635	Reversal of coronary atherosclerosis: Role of life style and medical management. Trends in Cardiovascular Medicine, 2018, 28, 524-531.	2.3	24
636	Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis. Journal of the National Cancer Institute, 2018, 110, 1035-1038.	3.0	84
637	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Current Cardiology Reports, 2018, 20, 55.	1.3	6

#	Article	IF	Citations
638	Mendelian randomization: Its impact on cardiovascular disease. Journal of Cardiology, 2018, 72, 307-313.	0.8	23
639	Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. Journal of the Endocrine Society, 2018, 2, 497-512.	0.1	19
640	Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. Journal of Clinical Lipidology, 2018, 12, 999-1007.	0.6	6
641	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. Clinical Pharmacology and Therapeutics, 2018, 104, 244-256.	2.3	14
642	Hipertrigliceridemia grave. CaracterÃsticas clÃnicas y manejo terapÃ©utico. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 217-223.	0.4	2
643	Effects of Apolipoprotein A-I/High-Density Lipoprotein Cholesterol onÂAtherosclerotic Vascular Disease. JACC Basic To Translational Science, 2018, 3, 210-212.	1.9	5
644	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. Journal of Clinical Lipidology, 2018, 12, 1290-1297.e1.	0.6	10
645	Unmet Need for AdjunctiveÂDyslipidemiaÂTherapy in Hypertriglyceridemia Management. Journal of the American College of Cardiology, 2018, 72, 330-343.	1.2	152
646	The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. Journal of Lipids, 2018, 2018, 1-9.	1.9	26
647	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association, 2018, 7, .	1.6	54
648	Natural approaches in metabolic syndrome management. Archives of Medical Science, 2018, 14, 422-441.	0.4	103
649	Treating Lipid Disorders in Athletes. , 2018, , 25-48.		0
650	Elevated level of lecithin:cholesterol acyltransferase (LCAT) is associated with reduced coronary atheroma burden. Atherosclerosis, 2018, 276, 131-139.	0.4	14
651	Peripheral Artery Disease. , 2018, , 2159-2167.e2.		0
652	Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. Seminars in Nephrology, 2018, 38, 369-382.	0.6	4
653	Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3019-3027.	1.8	74
654	Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World Journal of Diabetes, 2018, 9, 1-24.	1.3	145
655	Diabetes and Dislipidemia. Endocrinology, 2018, , 1-20.	0.1	0

#	Article	IF	Citations
656	Dyslipidemia. , 2018, , 353-360.		2
657	Hypercholesterolaemia â€“ practical information for non-specialists. Archives of Medical Science, 2018, 1, 1-21.	0.4	39
658	Effect of Serial Infusions of CER-001, a Pre-Î² High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. JAMA Cardiology, 2018, 3, 815.	3.0	135
659	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. JAMA Cardiology, 2018, 3, 806.	3.0	129
660	Secondary Prevention of Coronary Artery Disease. , 2018, , 479-487.		1
661	Insights From Pre-Clinical and Clinical Studies on the Role of Innate Inflammation in Atherosclerosis Regression. Frontiers in Cardiovascular Medicine, 2018, 5, 32.	1.1	37
662	Editorial commentary: Confessions of a drug dealer. Trends in Cardiovascular Medicine, 2018, 28, 532-533.	2.3	0
663	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine, 2018, 50, 461-484.	1.5	28
664	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Review of Cardiovascular Therapy, 2018, 16, 567-578.	0.6	11
665	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. International Journal of Molecular Sciences, 2018, 19, 1680.	1.8	41
666	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2018 Executive Summary. Endocrine Practice, 2018, 24, 91-121.	1.1	388
667	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. Current Cardiology Reports, 2018, 20, 71.	1.3	0
668	Pathophysiology of Diabetic Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 771-782.	0.9	271
669	Unravelling HDLâ€"Looking beyond the Cholesterol Surface to the Quality Within. International Journal of Molecular Sciences, 2018, 19, 1971.	1.8	51
670	Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease. Drugs, 2018, 78, 1171-1186.	4.9	21
671	Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention. Lipids in Health and Disease, 2018, 17, 21.	1.2	2
672	Improved insulin sensitivity and lower postprandial triglyceride concentrations after cold-pressed turnip rapeseed oil compared to cream in patients with metabolic syndrome. Diabetology and Metabolic Syndrome, 2018, 10, 38.	1.2	2
673	Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis. Journal of Clinical Lipidology, 2018, 12, 810-821.e1.	0.6	20

#	Article	IF	Citations
674	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. Current Cardiology Reports, 2018, 20, 88.	1.3	18
675	Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. Journal of Clinical Lipidology, 2018, 12, 1413-1419.	0.6	5
676	Assessment of omegaâ€3 carboxylic acids in statinâ€treated patients with high levels of triglycerides and low levels of highâ€density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clinical Cardiology, 2018, 41, 1281-1288.	0.7	151
677	High density lipoprotein cholesterol and cancer: Marker or causative?. Progress in Lipid Research, 2018, 71, 54-69.	5.3	79
678	HDL-cholesterol, genetics, and coronary artery disease: the myth of the â€˜good cholesterolâ€™?. European Heart Journal, 2018, 39, 2179-2182.	1.0	15
679	Niacin. Advances in Food and Nutrition Research, 2018, 83, 83-149.	1.5	64
680	Towards more specific treatment for diabetic dyslipidemia. Current Opinion in Lipidology, 2018, 29, 307-312.	1.2	14
681	PCSK9 in cholesterol metabolism: from bench to bedside. Clinical Science, 2018, 132, 1135-1153.	1.8	28
682	Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1Î² Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis. Cell Metabolism, 2018, 28, 432-448.e4.	7.2	64
683	Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	3.0	428
684	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Angiology, 2019, 70, 197-209.	0.8	18
685	Antiâ€ApoAâ€I IgG antibodies are not associated with carotid artery disease progression and firstâ€time cardiovascular events in middleâ€aged individuals. Journal of Internal Medicine, 2019, 285, 49-58.	2.7	4
686	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. Clinical Pharmacology and Therapeutics, 2019, 105, 568-581.	2.3	6
687	Dyslipidemia in Diabetes. , 2019, , 186-198.		3
688	High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes. Atherosclerosis, 2019, 282, 183-187.	0.4	6
689	Statin use and Vital Organ Failure in Patients With Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap: A Time-Dependent Population-Based Study. Frontiers in Pharmacology, 2019, 10, 889.	1.6	6
690	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	0.6	10
691	HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4114-4116.	1.8	6

#	Article	IF	Citations
692	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet, The, 2019, 394, 697-708.	6.3	67
693	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3939-3985.	1.8	42
694	Lp(a): Addressing a Target for Cardiovascular Disease Prevention. Current Cardiology Reports, 2019, 21, 102.	1.3	14
695	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Current Cardiology Reports, 2019, 21, 110.	1.3	24
696	Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?. JRSM Cardiovascular Disease, 2019, 8, 204800401986973.	0.4	3
697	Diabetes and Atherogenic Dyslipidemia. , 2019, , 587-596.		3
698	Repeated measures of extremely high levels of high-density lipoprotein cholesterol and subsequent all-cause mortality and cardiovascular events: A longitudinal study. Atherosclerosis, 2019, 288, 17-25.	0.4	11
699	HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2019, 20, 3514.	1.8	17
700	The Role of Niacin in the Management of Dyslipidemiaâ€. Journal of Clinical Lipidology, 2019, 13, e29-e30.	0.6	0
701	Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation, 2019, 140, 470-486.	1.6	170
702	Rounding the corner on residual risk: Implications of REDUCEâ€IT for omegaâ€3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clinical Cardiology, 2019, 42, 829-838.	0.7	13
703	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.4	1
704	Activation of HCAR2 by niacin: benefits beyond lipid lowering. Pharmacogenomics, 2019, 20, 1143-1150.	0.6	8
705	HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis, 2019, 291, 62-70.	0.4	142
706	Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?. Journal of Clinical Lipidology, 2019, 13, 873-879.	0.6	37
707	Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China. Scientific Reports, 2019, 9, 14426.	1.6	25
708	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of Clinical Lipidology, 2019, 13, 860-872.	0.6	79
709	Implications for REDUCE IT in clinical practice. Progress in Cardiovascular Diseases, 2019, 62, 395-400.	1.6	12

#	Article	IF	Citations
710	Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006073.	0.9	4
711	Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits. Canadian Journal of Cardiology, 2019, 35, 1400-1408.	0.8	11
712	Sea Change for Marine Omega-3s. Mayo Clinic Proceedings, 2019, 94, 2524-2533.	1.4	24
713	Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2041-2052.	1.1	22
714	2018 Guidelines for the Management of Dyslipidemia in Korea. Journal of Lipid and Atherosclerosis, 2019, 8, 78.	1.1	100
715	Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery. Cardiovascular Therapeutics, 2019, 2019, 1-9.	1.1	1
716	Elevated Triglycerides (â‰¥150 mg/dL) and High Triglycerides (200â€“499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients. CardioRenal Medicine, 2019, 9, 400-407.	0.7	14
717	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
718	Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2â€“Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. Clinical Therapeutics, 2019, 41, 1767-1777.	1.1	12
719	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes. Circulation, 2019, 140, 1308-1317.	1.6	172
720	PRavastatin Versus FlUVastatin After Statin Intolerance: The PRUV-Intolerance Study With Propensity Score Matching. American Journal of Medicine, 2019, 132, 1320-1326.e1.	0.6	4
721	Human T lymphotropic virus type 1 and risk of cardiovascular disease: Highâ€density lipoprotein dysfunction versus serum HDLâ€C concentrations. BioFactors, 2019, 45, 374-380.	2.6	4
722	Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Experimental Dermatology, 2019, 28, 15-22.	1.4	63
723	Heart Disease and Stroke Statisticsâ€”2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
724	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	2.0	124
725	Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients. Military Medical Research, 2019, 6, 2.	1.9	8
726	High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovascular Drugs and Therapy, 2019, 33, 207-219.	1.3	69
727	HDL cholesterol and ASCVD risk stratification: A debate. Atherosclerosis, 2019, 283, 7-12.	0.4	43

#	Article	IF	Citations
728	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 547.	1.6	14
729	High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3097-3107.	1.8	21
730	Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion. Cardiovascular Diabetology, 2019, 18, 82.	2.7	17
731	High-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3370-3378.	1.8	35
732	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. Journal of Clinical Lipidology, 2019, 13, 580-585.	0.6	16
733	Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men. Journal of Lipid Research, 2019, 60, 1457-1464.	2.0	27
734	Effects of Icosapent Ethyl on TotalÂIschemic Events. Journal of the American College of Cardiology, 2019, 73, 2791-2802.	1.2	208
735	Management of diabetic dyslipidemia: An update. World Journal of Diabetes, 2019, 10, 280-290.	1.3	58
736	Reproduction and longevity: A Mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease. SSM - Population Health, 2019, 8, 100411.	1.3	13
737	Antisense Oligonucleotides Targeting Lipoprotein(a). Current Atherosclerosis Reports, 2019, 21, 30.	2.0	38
738	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 374-392.	0.6	315
739	Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1277-1288.	0.9	18
740	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 75-88.	0.1	6
741	Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1253-1261.	1.1	35
742	Implications of altered NAD metabolism in metabolic disorders. Journal of Biomedical Science, 2019, 26, 34.	2.6	139
743	An updated review of lipidâ€modifying therapy. Medical Journal of Australia, 2019, 211, 87-92.	0.8	9
744	The time for lipoprotein(a) based intervention has arrived: where will the light shine?. Journal of Thoracic Disease, 2019, 11, S433-S436.	0.6	3
745	Residual cardiovascular risk among people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 28-38.	2.2	31

#	Article	IF	Citations
746	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 6-16.	2.2	13
747	Current Role of Lipoprotein Apheresis. Current Atherosclerosis Reports, 2019, 21, 26.	2.0	63
748	Diagnosis and Management of Dyslipidemia. , 2019, , 23-45.		0
749	Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes. Sleep, 2019, 42, .	0.6	25
750	Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications. International Journal of Molecular Sciences, 2019, 20, 974.	1.8	134
751	Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes. JAMA Network Open, 2019, 2, e190223.	2.8	16
752	Rethinking good cholesterol: a clinicians' guide to understanding HDL. Lancet Diabetes and Endocrinology,the, 2019, 7, 575-582.	5.5	38
753	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2019, 20, 917-928.	0.9	17
754	Trials in â€œTrueâ€•Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. Clinical Pharmacology and Therapeutics, 2019, 106, 960-967.	2.3	2
755	Lipoprotein(a)â€”antisense therapy. Clinical Research in Cardiology Supplements, 2019, 14, 51-56.	2.0	14
756	Cardiovascular Care in Patients With HIV. , 2019, , .		1
757	Drugs for Treatment of Dyslipidemia Available in theÂUSA. , 2019, , 171-195.		0
758	Guidelines impact cholesterol management. Journal of Clinical Lipidology, 2019, 13, 432-442.	0.6	6
759	Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes. JAMA Network Open, 2019, 2, e192224.	2.8	49
760	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
761	Evidence-Based Cardiovascular Risk Management in Diabetes. American Journal of Cardiovascular Drugs, 2019, 19, 439-448.	1.0	10
762	Highâ€density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort. Journal of Cellular Physiology, 2019, 234, 16168-16177.	2.0	10
763	New Frontiers in Lp(a)-Targeted Therapies. Trends in Pharmacological Sciences, 2019, 40, 212-225.	4.0	39

#	Article	IF	Citations
764	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. Current Diabetes Reports, 2019, 19, 13.	1.7	32
765	The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design. BMJ Open, 2019, 9, e025144.	0.8	26
766	Niacin: an old lipid drug in a new NAD+ dress. Journal of Lipid Research, 2019, 60, 741-746.	2.0	40
767	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2019 Executive Summary. Endocrine Practice, 2019, 25, 69-101.	1.1	245
768	Relation of Isolated Low High-Density Lipoprotein Cholesterol to Mortality and Cardiorespiratory Fitness (from the Henry Ford Exercise Testing Project [FIT Project]). American Journal of Cardiology, 2019, 123, 1429-1434.	0.7	3
769	Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines. Current Pharmacology Reports, 2019, 5, 87-97.	1.5	0
770	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2019. Diabetes Care, 2019, 42, S103-S123.	4.3	676
771	2018 Guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine, 2019, 34, 723-771.	0.7	144
772	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. , 0, , .		6
773	Prevalence of Dyslipidemia and Goal Attainment with Lipid-Lowering Therapy: Insights from Thai Multicenter Study and Overview of the Major Guidelines. , 2019, , .		0
774	The Role of Niacin in the Management of Dyslipidemia. , 0, , .		3
775	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. PLoS Biology, 2019, 17, e3000572.	2.6	29
776	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 428-437.	1.2	6
777	Effect of a Dual PPAR Î±/Î³ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial. Scientific Reports, 2019, 9, 19017.	1.6	25
778	Managing dyslipidemia for CVD prevention. Nurse Practitioner, 2019, 44, 8-16.	0.2	11
779	Molecular regulation of plasma lipid levels during systemic inflammation and sepsis. Current Opinion in Lipidology, 2019, 30, 108-116.	1.2	34
780	Updated management for patients with cardiovascular disease and diabetes. JAAPA: Official Journal of the American Academy of Physician Assistants, 2019, 32, 51-53.	0.1	2
781	Management of Hyperlipidemia After Stroke. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 93.	0.4	11

#	Article	IF	Citations
782	Cardiovascular risk reduction with icosapent ethyl. Current Opinion in Cardiology, 2019, 34, 721-727.	0.8	23
783	The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial. American Journal of Cardiovascular Drugs, 2019, 19, 49-57.	1.0	31
784	Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statinâ€controlled LDL cholesterol. Diabetes, Obesity and Metabolism, 2019, 21, 366-371.	2.2	90
785	Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: AÂsystematic review and meta-analysis. Journal of Clinical Lipidology, 2019, 13, 15-30.	0.6	48
786	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. European Heart Journal, 2019, 40, 2775-2781.	1.0	95
787	High-Density Lipoprotein and High-Density Lipoprotein Cholesterol. , 2019, , 61-69.		1
788	Riesgo cardiovascular residual de origen lipÃ¡dico. Componentes y aspectos fisiopatolÃ³gicos. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 75-88.	0.4	6
789	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
790	Cholesterol Lowering and Prevention of Stroke. Stroke, 2019, 50, 537-541.	1.0	27
791	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. American Journal of Cardiovascular Drugs, 2019, 19, 113-131.	1.0	4
792	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1144-e1161.	1.6	87
793	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, 3210-3227.	1.2	124
794	Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology, 2019, 12, 129-143.	1.3	29
795	Drug Therapy of Dyslipidemia in the Elderly. Drugs and Aging, 2019, 36, 321-340.	1.3	22
796	Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women. Journal of Clinical Lipidology, 2019, 13, 308-316.	0.6	6
797	HDL and cardiovascular disease. Pathology, 2019, 51, 142-147.	0.3	56
798	Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity. Journal of Lipid Research, 2019, 60, 594-608.	2.0	19
799	Small HDL subclass is associated with coronary plaque stability: An optical coherence tomography study in patients with coronary artery disease. Journal of Clinical Lipidology, 2019, 13, 326-334.e2.	0.6	4

#	Article	IF	Citations
800	Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology, 2019, 51, 227-232.	0.3	30
801	Dietary natural products as emerging lipoprotein(a)â€lowering agents. Journal of Cellular Physiology, 2019, 234, 12581-12594.	2.0	29
802	New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Current Atherosclerosis Reports, 2019, 21, 2.	2.0	87
803	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. Annual Review of Medicine, 2019, 70, 19-32.	5.0	6
804	Imaging as a surrogate marker of drug efficacy in cardiovascular disease. Heart, 2019, 105, 567-578.	1.2	13
805	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e38-e81.	1.1	431
806	Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 533-543.	0.8	42
808	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
809	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. Clinica Chimica Acta, 2019, 489, 189-195.	0.5	4
810	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. Trends in Cardiovascular Medicine, 2020, 30, 151-157.	2.3	3
811	Dyslipidemia Management in Adults With Diabetes. Canadian Journal of Diabetes, 2020, 44, 53-60.	0.4	49
812	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871
813	Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. European Journal of Preventive Cardiology, 2020, 27, 1255-1268.	0.8	33
814	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. American Journal of Cardiovascular Drugs, 2020, 20, 11-18.	1.0	0
815	High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: The CODAM study. Journal of Clinical Lipidology, 2020, 14, 122-132.e4.	0.6	19
816	Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 267-278.	1.1	78
817	Kidney disease trials for the 21st century: innovations in design and conduct. Nature Reviews Nephrology, 2020, 16, 173-185.	4.1	14
818	Niacin protects against abdominal aortic aneurysm formation via GPR109A independent mechanisms: role of NAD+/nicotinamide. Cardiovascular Research, 2020, 116, 2226-2238.	1.8	40

#	Article	IF	Citations
819	Niacin and hyperlipidemia. , 2020, , 263-281.		3
820	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	1.2	296
821	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. Drugs, 2020, 80, 229-239.	4.9	21
822	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	2.2	33
823	Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. European Journal of Pharmacology, 2020, 868, 172871.	1.7	3
824	Genetic disorders of lipoprotein metabolism. , 2020, , 245-265.		0
825	Effects of dietary niacin on liver health in genetically improved farmed tilapia (Oreochromis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502 T	0.7	3
826	Lipoprotein(a) Testing and Emerging Therapies. Cardiology in Review, 2020, 28, 250-255.	0.6	4
827	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. Atherosclerosis, 2020, 312, 60-65.	0.4	4
828	Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. European Heart Journal Supplements, 2020, 22, J21-J33.	0.0	7
829	Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!. Advanced Drug Delivery Reviews, 2020, 159, 94-119.	6.6	50
830	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. American Journal of Preventive Cardiology, 2020, 3, 100086.	1.3	10
831	Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. European Heart Journal Supplements, 2020, 22, J3-J20.	0.0	23
832	Statins in primary prevention: is the enthusiasm justified?. Indian Heart Journal, 2020, 72, 221-224.	0.2	0
833	Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome. Archives of Cardiovascular Diseases, 2020, 113, 617-629.	0.7	3
834	Management of hypertriglyceridemia. BMJ, The, 2020, 371, m3109.	3.0	89
835	When to lower triglycerides?. Current Opinion in Lipidology, 2020, 31, 238-245.	1.2	9
836	Use of Run-in Periods in Randomized Trials. JAMA - Journal of the American Medical Association, 2020, 324, 188.	3.8	12

#	Article	IF	Citations
837	Metabolic and cardiovascular outcomes of bariatric surgery. Current Opinion in Lipidology, 2020, 31, 246-256.	1.2	14
838	Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 2623-2636.	2.0	45
839	Use of nonâ€ŁDLâ€€C lipidâ€łowering medications in patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00126.	1.0	1
840	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 1196-1224.	1.1	117
841	Hitos histÃ³ricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteina convertasa subtilisina/kexina tipo 9. Revista Espanola De Cardiologia Suplementos, 2020, 20, 8-14.	0.2	0
842	Icosapent Ethyl: Niche Drug or for the Masses?. Current Cardiology Reports, 2020, 22, 104.	1.3	8
843	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy, 2020, 21, 2137-2151.	0.9	7
844	Effects of Eicosapentaenoic Acid on Arterial Calcification. International Journal of Molecular Sciences, 2020, 21, 5455.	1.8	8
845	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. European Heart Journal, 2020, 41, 3336-3342.	1.0	27
846	Applicability of the <scp>REDUCEâ€IT</scp> trial to the <scp>FASTâ€MI</scp> registry. Are the results of randomized trials relevant in routine clinical practice?. Clinical Cardiology, 2020, 43, 1260-1265.	0.7	11
847	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 2020, 159, 4-33.	6.6	113
848	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
849	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2020. Diabetes Care, 2020, 43, S111-S134.	4.3	421
850	Cholesteryl ester transfer protein inhibitors in precision medicine. Clinica Chimica Acta, 2020, 510, 733-740.	0.5	4
851	¹⁸ F-Fluorodeoxyglucose-Positron Emission Tomography Imaging Detects Response to Therapeutic Intervention and Plaque Vulnerability in a Murine Model of Advanced Atherosclerotic Diseaseâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2821-2828.	1.1	10
852	The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. Current Diabetes Reports, 2020, 20, 65.	1.7	18
853	Novel aspects on the role of white adipose tissue in type 2 diabetes. Current Opinion in Pharmacology, 2020, 55, 47-52.	1.7	8
854	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63

#	Article	IF	Citations
855	Effect of niacin monotherapy on high density lipoprotein composition and function. Lipids in Health and Disease, 2020, 19, 190.	1.2	8
856	Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus. Scientific Reports, 2020, 10, 14158.	1.6	8
857	NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death. Frontiers in Physiology, 2020, 11, 901.	1.3	20
858	Antiâ€inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016507.	1.6	21
859	Prevention of Stroke by Lowering Blood Cholesterol Concentrations. , 2020, , 297-307.		0
860	The role of intracoronary imaging in translational research. Cardiovascular Diagnosis and Therapy, 2020, 10, 1480-1507.	0.7	3
861	Tackling cardiometabolic risk in the Asia Pacific region. American Journal of Preventive Cardiology, 2020, 4, 100096.	1.3	5
862	Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis. International Journal of Molecular Sciences, 2020, 21, 8263.	1.8	24
863	Hypertriglyceridemia: new approaches in management and treatment. Current Opinion in Lipidology, 2020, 31, 331-339.	1.2	27
864	Prevalence of US Adults with Triglyceridesâ€‰â‰¥â€‰150Âmg/dl: NHANES 2007â€“2014. Cardiology and Therapy, 2020, 9, 207-213.	1.1	35
865	Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome. Atherosclerosis, 2020, 303, 21-28.	0.4	9
866	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 88.	1.1	82
867	Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Annals of Medicine, 2020, 52, 162-177.	1.5	32
868	Association of hyperlipidaemia with 5-year survival after hospitalisation for acute myocardial infarction: a propensity score matched analysis. Open Heart, 2020, 7, e001163.	0.9	5
869	ApoE and apoC-III-defined HDL subtypes: a descriptive study of their lecithin cholesterol acyl transferase and cholesteryl ester transfer protein content and activity. Lipids in Health and Disease, 2020, 19, 106.	1.2	11
870	Omega-3 fatty acid therapy for cardiovascular disease: justified or not?. Current Opinion in Cardiology, 2020, 35, 417-422.	0.8	3
871	Lipoprotein(a) and calcific aortic valve stenosis: A systematic review. Progress in Cardiovascular Diseases, 2020, 63, 496-502.	1.6	21
872	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Research and Care, 2020, 8, e000943.	1.2	15

#	Article	IF	Citations
873	The mystery of evacetrapib - why are CETP inhibitors failing?. Expert Review of Cardiovascular Therapy, 2020, 18, 127-130.	0.6	12
874	Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1135-1147.	1.1	240
875	Challenges and practical recommendations for successfully recruiting inactive, statin-free older adults to clinical trials. BMC Research Notes, 2020, 13, 174.	0.6	2
876	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 371-385.	1.5	9
877	Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment. Current Cardiology Reports, 2020, 22, 22.	1.3	41
878	HDL cholesterol and apolipoprotein A-I concentrations and risk of atherosclerotic cardiovascular disease: Human genetics to unravel causality. Atherosclerosis, 2020, 299, 53-55.	0.4	12
879	The B-vitamins. , 2020, , 217-239.		4
880	Cholesterol mass efflux capacity and risk of peripheral artery disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2020, 297, 81-86.	0.4	8
881	The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients, 2020, 12, 605.	1.7	109
882	Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy. Journal of Cardiology, 2020, 76, 66-72.	0.8	6
883	Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study. Atherosclerosis, 2020, 299, 56-63.	0.4	47
884	NAD+ homeostasis in health and disease. Nature Metabolism, 2020, 2, 9-31.	5.1	351
885	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
886	The Rise and Fall â€œingâ€•of the HDL Hypothesis. Drugs, 2020, 80, 353-362.	4.9	7
887	Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes. Atherosclerosis, 2020, 300, 10-18.	0.4	6
888	What do we know about the role of lipoprotein(a) in atherogenesis 57Âyears after its discovery?. Progress in Cardiovascular Diseases, 2020, 63, 219-227.	1.6	35
889	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). European Heart Journal, 2020, 41, 2262-2271.	1.0	65
890	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 107-139.	1.1	410

#	Article	IF	Citations
891	High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis, 2020, 302, 36-42.	0.4	59
892	HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. European Journal of Preventive Cardiology, 2020, 27, 1187-1203.	0.8	72
893	Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study. Trials, 2020, 21, 353.	0.7	2
894	Statins and PCSK9 inhibitors: A new lipid-lowering therapy. European Journal of Pharmacology, 2020, 878, 173114.	1.7	54
895	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. Journal of Women's Health, 2020, 29, 1091-1100.	1.5	9
896	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	1.6	157
897	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. Trends in Cardiovascular Medicine, 2021, 31, 305-311.	2.3	13
898	HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. European Journal of Preventive Cardiology, 2021, 28, 166-173.	0.8	26
899	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
900	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. Annual Review of Medicine, 2021, 72, 447-458.	5.0	12
901	LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Seminars in Cancer Biology, 2021, 73, 134-157.	4.3	30
902	Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. Expert Review of Clinical Pharmacology, 2021, 14, 79-93.	1.3	21
903	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€"2021. Diabetes Care, 2021, 44, S125-S150.	4.3	359
904	Simvastatinâ€"Ezetimibe enhances growth factor expression and attenuates neuron loss in the hippocampus in a model of intracerebral hemorrhage. Fundamental and Clinical Pharmacology, 2021, 35, 634-644.	1.0	6
905	Diabetogenic effects of cardioprotective drugs. Diabetes, Obesity and Metabolism, 2021, 23, 877-885.	2.2	13
906	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgraduate Medicine, 2021, 133, 28-41.	0.9	10
907	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiology, 2021, 17, 155-174.	0.5	14
908	Learning by experience. , 2021, , 455-462.		0

#	Article	IF	Citations
909	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. Contemporary Cardiology, 2021, , 1-22.	0.0	0
910	Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	7
911	Lipoprotein and Lipid Metabolism. , 2021, , 235-278.		2
912	Diabetes, Lipids, and CV Risk. Current Atherosclerosis Reports, 2021, 23, 8.	2.0	6
913	High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study. Journal of Atherosclerosis and Thrombosis, 2021, , .	0.9	2
914	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. Biomaterials Science, 2021, 9, 3185-3208.	2.6	5
915	Fibrate and Niacin. Stroke Revisited, 2021, , 103-110.	0.2	0
917	Development and Validation of a Predictive Model for Coronary Artery Disease Using Machine Learning. Frontiers in Cardiovascular Medicine, 2021, 8, 614204.	1.1	9
918	APOA1: a Protein with Multiple Therapeutic Functions. Current Atherosclerosis Reports, 2021, 23, 11.	2.0	72
919	Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention andÂTreatment. Journal of the American College of Cardiology, 2021, 77, 423-436.	1.2	48
920	Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA₂â€mediated adverse reactions? A combined epidemiologicalâ€experimental approach. British Journal of Clinical Pharmacology, 2021, 87, 3813-3824.	1.1	7
922	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). Journal of the American College of Cardiology, 2021, 77, 1576-1589.	1.2	86
923	Atherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice. Circulation Research, 2021, 128, 690-705.	2.0	18
924	Influence of lipid-lowering drugs on inflammation: what is yet to be done?. Archives of Medical Science, 2021, , .	0.4	6
925	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. Cardiovascular Drugs and Therapy, 2021, 35, 677-690.	1.3	11
926	Mechanisms and Treatment of Dyslipidemia in Diabetes. Current Cardiology Reports, 2021, 23, 26.	1.3	39
927	Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study. Cardiovascular Diabetology, 2021, 20, 72.	2.7	7
928	The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies. Pharmacological Research, 2021, 165, 105446.	3.1	1

#	Article	IF	Citations
929	Triglycerides and cardiovascular disease. Current Opinion in Cardiology, 2021, 36, 469-477.	0.8	19
930	Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment. Journal of Lipids, 2021, 2021, 1-11.	1.9	15
932	Effects of omega-3 fatty acids, vitamins, and chelation therapy in patients with heart diseases. Journal of Medicine and Life Science, 2021, 18, 1-10.	0.1	0
933	Editorial commentary: A new era for preventive cardiology. Trends in Cardiovascular Medicine, 2022, 32, 195-197.	2.3	0
934	Causal Language in Observational Orthopaedic Research. Journal of Bone and Joint Surgery - Series A, 2021, 103, e76.	1.4	12
935	HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 4547.	1.8	28
936	Umbrella Review on Non-Statin Lipid-Lowering Therapy. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 107424842110029.	1.0	11
937	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
938	Cardiovascular effects of omega-3 fatty acids: Hope or hype?. Atherosclerosis, 2021, 322, 15-23.	0.4	19
939	High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nature Reviews Cardiology, 2021, 18, 712-723.	6.1	91
940	High Density Lipoproteins and Diabetes. Cells, 2021, 10, 850.	1.8	34
941	EPAâ€™s pleiotropic mechanisms of action: a narrative review. Postgraduate Medicine, 2021, 133, 1-14.	0.9	22
943	Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies. Cardiovascular Research, 2022, 118, 1330-1343.	1.8	24
944	Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies. BMJ Global Health, 2021, 6, e005222.	2.0	8
945	High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. Circulation, 2021, 143, 1935-1945.	1.6	67
946	High-Density Lipoprotein Cholesterol and the Risk of First Ischemic Stroke in a Chinese Hypertensive Population. Clinical Interventions in Aging, 2021, Volume 16, 801-810.	1.3	8
948	Doseâ€“Response Association Between High-Density Lipoprotein Cholesterol and Stroke: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Preventing Chronic Disease, 2021, 18, E45.	1.7	11
949	Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nature Reviews Nephrology, 2021, 17, 528-542.	4.1	70

#	Article	IF	Citations
950	Patient perceptions and use of nonâ€statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. Clinical Cardiology, 2021, 44, 863-870.	0.7	2
951	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. Journal of Clinical Medicine, 2021, 10, 2233.	1.0	15
952	ApoA-I mimetic does not improve left ventricular diastolic dysfunction in rabbits without aortic valve stenosis. International Journal of Cardiology, 2021, 331, 199-205.	0.8	0
953	Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol. Coronary Artery Disease, 2021, Publish Ahead of Print, e51-e58.	0.3	0
954	Pharmacological Management of Hyperlipidemia in Older Individuals. , 2021, 36, 284-303.		1
955	Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases. Life, 2021, 11, 581.	1.1	11
956	Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2330-2341.	1.1	14
957	Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. Journal of Clinical Lipidology, 2021, 15, 545-555.	0.6	7
958	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 107424842110236.	1.0	4
959	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	0.9	14
960	Advancing Beyond Failed HDL Clinical Trials to Pharmacogenetic Studies of ADCY9 and CETP inhibition. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, 496-500.	0.8	1
961	Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus. World Journal of Diabetes, 2021, 12, 1070-1080.	1.3	13
963	Trends in lipid-modifying agent use in 83 countries. Atherosclerosis, 2021, 328, 44-51.	0.4	57
964	Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23Âyears follow-up of two US cohort studies. Journal of Translational Medicine, 2021, 19, 286.	1.8	9
965	High-Density Lipoproteins in Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 8201.	1.8	9
966	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. European Heart Journal, 2021, 42, 4324-4332.	1.0	135
967	The current landscape of lipoprotein(a) in calcific aortic valvular disease. Current Opinion in Cardiology, 2021, 36, 542-548.	0.8	4
968	Environmental Factors Modifying HDL Functionality. Current Medicinal Chemistry, 2022, 29, 1687-1701.	1.2	1

#	Article	IF	Citations
969	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells, 2021, 10, 1869.	1.8	46
970	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2828-2839.	1.8	10
971	Lipoprotein (a): When to Measure and How to Treat?. Current Atherosclerosis Reports, 2021, 23, 51.	2.0	18
972	HDL and type 2 diabetes: the chicken or the egg?. Diabetologia, 2021, 64, 1917-1926.	2.9	34
973	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. Nutrients, 2021, 13, 2748.	1.7	28
974	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. European Journal of Preventive Cardiology, 2022, 29, 739-755.	0.8	8
975	HDL-C, longitudinal change and risk of mortality in a Chinese cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2669-2677.	1.1	5
976	Sphingolipids in HDL â€“ Potential markers for adaptation to pregnancy?. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158955.	1.2	9
978	Lipoprotein(a) Testing Patterns in a Large Health System. American Journal of Cardiology, 2021, 153, 43-50.	0.7	8
979	Diabetic dyslipidaemia. Practical Laboratory Medicine, 2021, 26, e00248.	0.6	14
980	Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes. , 2021, , 58-64.		0
981	A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice. Vaccine, 2021, 39, 5780-5786.	1.7	13
982	Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. Expert Opinion on Drug Safety, 2022, 21, 31-42.	1.0	7
983	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. Vascular Health and Risk Management, 2021, Volume 17, 527-542.	1.0	15
984	Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction. American Journal of Medicine, 2021, 134, 1085-1090.	0.6	27
985	Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases. Biomedicines, 2021, 9, 1271.	1.4	18
986	Preventive Cardiology. , 2022, , 341-375.		0
987	Genetic evidence for independent causal relationships between metabolic biomarkers and risk of coronary artery diseases. Journal of Lipid Research, 2021, 62, 100064.	2.0	1

#	Article	IF	Citations
988	Lipoprotein(a) and kidney diseases. Nephrology (Saint-Petersburg), 2021, 25, 31-46.	0.1	0
989	Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis. Diabetology and Metabolic Syndrome, 2021, 13, 15.	1.2	4
991	Genetic Variation in Sodiumâ€glucose Cotransporter 2 and Heart Failure. Clinical Pharmacology and Therapeutics, 2021, 110, 149-158.	2.3	11
993	Multicenter Trials. , 2015, , 501-518.		5
994	What Is the Question?. , 2015, , 49-71.		1
995	Stable Ischemic Heart Disease Stable Ischemic Heart Disease. , 2015, , 2109-2172.		1
996	Stable Ischemic Heart Disease. , 2014, , 1-70.		1
997	Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations. Cardiology and Therapy, 2020, 9, 275-292.	1.1	10
998	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	3.1	56
999	Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. Clinical Science, 2019, 133, 2221-2235.	1.8	24
1000	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnosticâ€“therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
1001	Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?. Current Opinion in Lipidology, 2020, 31, 125-131.	1.2	15
1005	Plasminogen promotes cholesterol efflux by the ABCA1 pathway. JCI Insight, 2017, 2, .	2.3	36
1006	2016 Chinese guidelines for the management of dyslipidemia in adults. Journal of Geriatric Cardiology, 2018, 15, 1-29.	0.2	226
1007	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. F1000Research, 2017, 6, 134.	0.8	63
1008	Assessment of Competition between Fisheries and Steller Sea Lions in Alaska Based on Estimated Prey Biomass, Fisheries Removals and Predator Foraging Behaviour. PLoS ONE, 2015, 10, e0123786.	1.1	11
1009	Efficacy of Supplementation with B Vitamins for Stroke Prevention: A Network Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0137533.	1.1	19
1010	Increased cardiovascular risk associated to hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. Anatolian Journal of Cardiology, 2019, 23, 60-69.	0.5	4

#	Article	IF	Citations
1011	High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes. Methodist DeBakey Cardiovascular Journal, 2021, 15, 55.	0.5	20
1012	Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment. Methodist DeBakey Cardiovascular Journal, 2021, 15, 179.	0.5	34
1013	Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA). British Journal of Diabetes, 2017, 17, 64.	0.1	17
1014	Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes. British Journal of Diabetes, 2018, 18, 101-105.	0.1	4
1015	The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. European Cardiology Review, 2014, 9, 65.	0.7	6
1016	Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes. US Cardiology Review, 2019, 13, 49-53.	0.5	6
1017	Statin-Associated Muscle Adverse Events: Update for clinicians. Sultan Qaboos University Medical Journal, 2016, 16, e406-415.	0.3	10
1018	Positive association of familial longevity with the moderate-high HDL-C concentration in Bama Aging Study. Aging, 2018, 10, 3528-3540.	1.4	16
1019	Low Levels of High-Density Lipoprotein Cholesterol Do Not Predict the Incidence of Type 2 Diabetes in an Iranian High-Risk Population: The Isfahan Diabetes Prevention Study. Review of Diabetic Studies, 2016, 13, 187-196.	0.5	1
1020	Comparison of M6-C and Mobi-C cervical total disc replacement for cervical degenerative disc disease in adults. Journal of Spine Surgery, 2019, 5, 393-403.	0.6	7
1021	CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?. Global Cardiology Science & Practice, 2017, 2016, e201634.	0.3	7
1022	Pharmacological Effects of Niacin on Acute Hyperlipemia. Current Medicinal Chemistry, 2016, 23, 2826-2835.	1.2	12
1023	Cardioprotective Properties of HDL: Structural and Functional Considerations. Current Medicinal Chemistry, 2020, 27, 2964-2978.	1.2	19
1024	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. Current Drug Metabolism, 2019, 20, 72-82.	0.7	12
1025	Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies. Current Cardiology Reviews, 2018, 14, 67-76.	0.6	33
1026	Role of niacin in current clinical practice. Minerva Medica, 2019, 110, 79-83.	0.3	8
1027	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. Journal of Cardiovascular Medicine, 2021, 22, 151-161.	0.6	53
1028	The Treatment of Disorders of Lipid Metabolism. Deutsches Ärzteblatt International, 2016, 113, 261-8.	0.6	55

#	Article	IF	Citations
1029	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	1.3	28
1030	The Use of a Hydrogel Matrix for Controlled Delivery of Niacin to the Gastrointestinal Tract for Treatment of Hyperlipidemia. Physiological Research, 2015, 64, S51-S60.	0.4	6
1031	Treatment of Hypertriglyceridemia: a Review of Current Options. Physiological Research, 2015, 64, S331-S340.	0.4	22
1032	Familial hypercholesterolemia: Detect, treat, and ask about family. Cleveland Clinic Journal of Medicine, 2020, 87, 109-120.	0.6	12
1033	HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. Cardiovascular Diagnosis and Therapy, 2016, 6, 34-43.	0.7	13
1034	Effects of B Vitamins Overload on Plasma Insulin Level and Hydrogen Peroxide Generation in Rats. Chinese Journal of Physiology, 2017, 60, 207-214.	0.4	2
1035	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. Diabetes and Metabolism Journal, 2020, 44, 213.	1.8	43
1036	Pleiotropic effects of apolipoprotein A-â...¡ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis. Journal of Biomedical Research, 2020, 34, 14.	0.7	9
1037	Therapeutic management of hyperlipoproteinemia (a). Drugs in Context, 2019, 8, 1-11.	1.0	14
1038	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications, 2021, 12, 5640.	5.8	57
1039	Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor. Global Cardiology Science & Practice, 2021, 2021, e202119.	0.3	2
1040	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
1041	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. JAMA Internal Medicine, 2021, 181, 1575.	2.6	28
1042	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	1.2	42
1043	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATV0000000000000147.	1.1	207
1044	A Modern Approach to Dyslipidemia. Endocrine Reviews, 2022, 43, 611-653.	8.9	110
1045	Challenges in Optimizing Lipid Management in Women. Cardiovascular Drugs and Therapy, 2022, 36, 1197-1220.	1.3	6
1046	Changes of lipoprotein(a) levels with endogenous steroid hormones. European Journal of Clinical Investigation, 2021, , e13699.	1.7	1

#	Article	IF	Citations
1047	Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. Journal of the Japanese Coronary Association, 2014, 20, 282-294.	0.0	0
1050	Study of Coronary Risk Factors in Rural Malaysia Population. International Journal of Medical Biology, 2015, 2, 1-7.	0.0	1
1051	Cholesteryl Ester Transfer Protein Inhibitors â€“ Future Soon to be REVEALed. European Cardiology Review, 2015, 10, 64.	0.7	0
1052	Hyperlipidemia: Where Is the Evidence for Combination Therapy?. , 2015, , 123-126.		0
1053	Closeout. , 2015, , 463-477.		0
1054	Update on the Pharmacologic Agents for Dyslipidemia. Journal of Korean Diabetes, 2015, 16, 269.	0.1	0
1057	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2016, , 331-354.		0
1058	Stable Ischemic Heart Disease. , 2016, , 1-70.		5
1059	8. Sphingosine-1-phosphate-rich high-density lipoprotein in cardiovascular health and disease. Human Health Handbooks, 2016, , 137-154.	0.1	0
1061	Recurrent Cardiac Events Driven by Prothrombotic Burden in a Patient Undergoing Lipoprotein Apheresis for High Lp(a) Levels. , 2017, 1, 001-005.		0
1062	The target level and the difference of pathway on lipid lowering therapy. Journal of the Japanese Coronary Association, 2017, 23, 165-169.	0.0	0
1063	Platelet Prostanoids and their receptors. , 2017, , 203-211.		1
1064	Hyperlipidemia. , 2017, , .		0
1065	Dyslipidemia. , 2017, , .		0
1066	Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease. Oncotarget, 2018, 9, 9489-9497.	0.8	5
1067	What has changed in treatment of patients with dyslipidemia?. Interni Medicina Pro Praxi, 2017, 19, 106-108.	0.0	0
1070	Diabetes and Dislipidemia. Endocrinology, 2018, , 51-70.	0.1	0
1071	The High Density Lipoprotein Cholesterol Hypothesis Revisited. Indonesian Biomedical Journal, 2018, 10, 84-103.	0.2	0

#	Article	IF	Citations
1074	Combined lipid-lowering therapy. Vnitrni Lekarstvi, 2018, 64, 1177-1184.	0.1	0
1075	Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities. Vnitrni Lekarstvi, 2018, 64, 1160-1168.	0.1	2
1076	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
1077	Cholesterol: Canâ€™t Live With It, Canâ€™t Live Without It. Methodist DeBakey Cardiovascular Journal, 2021, 15, 9.	0.5	8
1078	Effect of Niacin on Carotid Atherosclerosis in Patients at Low-Density Lipoprotein-Cholesterol Goal but High Lipoprotein (a) Level: a 2-Year Follow-Up Study. Journal of Lipid and Atherosclerosis, 2019, 8, 58.	1.1	3
1079	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
1081	Lipoprotein(a): the underutilized risk factor for cardiovascular disease. Global Cardiology Science & Practice, 2019, 2019, e201911.	0.3	0
1082	Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". International Journal of Health Policy and Management, 2020, 9, 352-355.	0.5	1
1083	Large-scale randomized evidence: Trials and meta-analyses of trials. , 2020, , 51-66.		0
1084	Regulation of NAD+ metabolism in aging and disease. Metabolism: Clinical and Experimental, 2022, 126, 154923.	1.5	40
1085	Management of Hypertriglyceridemia (Including Fibrates and n-3 FattyÂAcids). Contemporary Cardiology, 2021, , 295-306.	0.0	1
1086	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 104-113.	1.2	2
1087	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology, 2021, , 139-158.	0.0	2
1088	High-Density Lipoproteins. Contemporary Cardiology, 2021, , 341-361.	0.0	1
1089	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. Contemporary Cardiology, 2021, , 121-138.	0.0	0
1090	Lipoprotein (a): Principles from Bench to Bedside. Contemporary Cardiology, 2021, , 363-381.	0.0	0
1091	Cardiovascular Disease in Women: Focus on Lipid Management. Contemporary Cardiology, 2021, , 467-487.	0.0	0
1092	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Global Cardiology Science & Practice, 2020, 2020, e202039.	0.3	2

#	Article	IF	Citations
1093	Management of Dyslipidaemia in the Elderly. Contemporary Cardiology, 2021, , 489-505.	0.0	0
1094	High-density lipoproteins (HDL): Novel function and therapeutic applications. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159058.	1.2	17
1095	HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease â€“ Insights from randomized clinical trials and human genetics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159063.	1.2	19
1096	Diabetes and Dyslipidemia. Endocrinology, 2020, , 51-70.	0.1	0
1097	Clinical Management of SAMS. Contemporary Cardiology, 2020, , 71-77.	0.0	0
1098	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2020, , 387-411.		0
1099	Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses. Korean Circulation Journal, 2020, 50, 91.	0.7	7
1100	Atherogenic dyslipidemia typical for metabolic syndrome. Vnitrni Lekarstvi, 2020, 66, 15-20.	0.1	0
1102	High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?. Vascular Pharmacology, 2021, 141, 106928.	1.0	7
1103	Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e899-e911.	1.8	31
1107	A vitaminic boost to rock the aortic wall. Cardiovascular Research, 2020, 116, 2175-2176.	1.8	0
1108	Primary Prevention of Coronary Artery Disease. , 2021, , 81-123.		0
1109	Stable Ischemic Heart Disease. , 2021, , 125-154.		0
1110	"Niacin Doesn't Work and Is Harmful!" Proclaim the Headlines. Yet Another Highly Publicized Questionable Study to Discredit Integrative Medicine. Integrative Medicine, 2014, 13, 8-11.	0.1	2
1111	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Canadian Family Physician, 2016, 62, 32-7.	0.1	36
1112	Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. American Health and Drug Benefits, 2016, 9, 123-6.	0.5	9
1113	Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?. Topics in Antiviral Medicine, 2016, 23, 169-73.	0.1	4
1114	Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. Integrative Medicine, 2020, 19, 22-27.	0.1	0

#	Article	IF	Citations
1115	Vitamins and minerals as nutraceuticals in cardiovascular diseases and other chronic diseases. , 2022, , 651-670.		0
1116	Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial. Diabetes Care, 2022, 45, 241-250.	4.3	6
1117	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I WiadomoÅ›ci PTDL, 2021, 57, 1-99.	0.0	0
1118	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle SociÃ©tÃ© Francophone dâ€™AthÃ©rosclÃ©rose (NSFA). Archives of Cardiovascular Diseases, 2021, 114, 828-847.	0.7	9
1119	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. Lipids in Health and Disease, 2021, 20, 170.	1.2	6
1120	NAD ⁺ Metabolism in Cardiac Health, Aging, and Disease. Circulation, 2021, 144, 1795-1817.	1.6	64
1121	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.4	78
1122	The dawn of a new era of targeted lipid-lowering therapies. European Heart Journal, 2022, 43, 3198-3208.	1.0	48
1123	KardiovaskulÃre Prophylaxe: Wenn man Surrogatmarker â€žtherapiertâ€œ. , 0, , .		0
1124	HDL colesterol, protector de enfermedad cardiovascular: calidad vs. cantidad. Revista De InvestigaciÃ“n De La Universidad Norbert Wiener, 2016, 5, 95-108.	0.0	0
1125	High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?. Handbook of Experimental Pharmacology, 2021, , 157-200.	0.9	3
1126	Lipoprotein(a). Handbook of Experimental Pharmacology, 2021, , 201-232.	0.9	22
1127	Real-world utilization of bempedoic acid in an academic preventive cardiology practice. Journal of Clinical Lipidology, 2022, 16, 94-103.	0.6	16
1128	Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality. American Journal of Cardiology, 2022, 167, 43-53.	0.7	21
1129	Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular Drugs and Therapy, 2023, 37, 683-694.	1.3	8
1130	NAD+-Increasing Strategies to Improve Cardiometabolic Health?. Frontiers in Endocrinology, 2021, 12, 815565.	1.5	4
1131	Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. American Journal of Cardiology, 2022, 168, 11-16.	0.7	10
1132	U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study. Stroke, 2022, 53, 1624-1632.	1.0	19

#	Article	IF	Citations
1133	Association of major blood lipids with postâ€stroke dementia: A communityâ€based cohort study. European Journal of Neurology, 2022, 29, 968-979.	1.7	2
1134	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis, 2022, 343, 28-50.	0.4	12
1135	The Role of Physical Activity and Exercise in Preventive Cardiology. Medical Clinics of North America, 2022, 106, 249-258.	1.1	1
1136	LCAT- targeted therapies: Progress, failures and future. Biomedicine and Pharmacotherapy, 2022, 147, 112677.	2.5	18
1137	HDL maturation and remodelling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159119.	1.2	3
1138	Radical Thinking: Scientific Rigor and Pragmatism. Statistics in Biopharmaceutical Research, 0, , 1-13.	0.6	4
1139	The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity. Atherosclerosis, 2022, 345, 1-6.	0.4	4
1140	High-density lipoprotein cholesterol â€" friend or enemy?. Kazan Medical Journal, 2022, 103, 79-88.	0.1	0
1141	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€"2022. Diabetes Care, 2022, 45, S144-S174.	4.3	282
1142	Effects of nonâ€steroidal antiâ€inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2337-2354.	2.7	9
1143	Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.3	2
1144	Approach to the Patient With Moderate Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1686-1697.	1.8	5
1145	Contemporary Management of Dyslipidemia. Drugs, 2022, 82, 559-576.	4.9	14
1146	Relationship between dietary niacin intake and diabetes mellitus in the National Health and Nutrition Examination Survey (NHANES) 2003â€"2018. Eating and Weight Disorders, 2022, 27, 2425-2434.	1.2	4
1147	Targeting triglycerides to lower residual cardiovascular risk. Expert Review of Cardiovascular Therapy, 2022, , 1-7.	0.6	2
1148	Macrophage SR-B1 in atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2022, 33, 167-174.	1.2	4
1149	The Role of High-Density Lipoprotein Cholesterol in 2022. Current Atherosclerosis Reports, 2022, 24, 365-377.	2.0	14
1150	Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis. Nutrients, 2022, 14, 1480.	1.7	8

#	Article	IF	Citations
1151	High-Density Lipoprotein Is Associated with Leukoaraiosis Severity in Patients with Acute Ischemic Stroke. Neurotoxicity Research, 2022, , 1.	1.3	0
1153	Approach to patients with hypertriglyceridemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101659.	2.2	2
1158	Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review. Vascular Medicine, 2022, 27, 385-391.	0.8	7
1159	Clinical strategies for reducing cholesterol levels. , 2022, , 853-901.		0
1160	Association of High-Density Lipoprotein Cholesterol Phenotypes with the Risk of Cardiovascular Diseases and Mortality: A Cohort Study in Korea. Endocrinology and Metabolism, 2022, 37, 261-271.	1.3	3
1161	Coenzyme Q10 supplementation improves cholesterol efflux capacity and antiinflammatory properties of high-density lipoprotein in Chinese adults with dyslipidemia. Nutrition, 2022, 101, 111703.	1.1	7
1162	Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice. , 0, 1, .		1
1163	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Current Atherosclerosis Reports, 2022, 24, 585-597.	2.0	8
1164	Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program. Communications Biology, 2022, 5, 362.	2.0	5
1165	Remnant Cholesterol Predicts Risk of Cardiovascular Events in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries. Journal of the American Heart Association, 2022, 11, e024366.	1.6	17
1166	HDL and Diabetes. Advances in Experimental Medicine and Biology, 2022, 1377, 119-127.	0.8	4
1167	Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). American Heart Journal, 2022, 251, 61-69.	1.2	40
1168	Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. JAMA Cardiology, 2022, 7, 672.	3.0	66
1169	NAD⁺ and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities. Journal of Lipid and Atherosclerosis, 2022, 11, 111.	1.1	7
1170	HDL as Bidirectional Lipid Vectors: Time for New Paradigms. Biomedicines, 2022, 10, 1180.	1.4	5
1171	Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis, 2022, 349, 110-122.	0.4	36
1172	Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2182-2194.	1.8	6
1173	A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukotrienes and Essential Fatty Acids, 2022, 182, 102450.	1.0	14

#	Article	IF	Citations
1174	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. American Heart Journal Plus, 2022, 17, 100148.	0.3	4
1175	Omega-3-fatty acids: Do they prevent cardiovascular disease?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101681.	2.2	5
1176	NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. Journal of Clinical Lipidology, 2022, 16, 361-375.	0.6	56
1177	Adequate enrollment of women in cardiovascular drug trials and the need for sex-specific assessment and reporting. American Heart Journal Plus, 2022, , 100155.	0.3	0
1178	Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial. Nephrology Dialysis Transplantation, 2023, 38, 982-991.	0.4	3
1179	Impact of different training modalities on highâ€density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial. ESC Heart Failure, 2022, 9, 3019-3030.	1.4	3
1180	Plasma Homocysteine Level Is Independently Associated With Conventional Atherogenic Lipid Profile and Remnant Cholesterol in Adults. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
1181	Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years. Korean Journal of Clinical Laboratory Science, 2022, 54, 95-102.	0.1	0
1182	Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort. Diabetes Care, 2022, 45, 2136-2143.	4.3	13
1183	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, 51, 655-679.	1.2	7
1184	New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	3
1186	Evaluation and Management of Lipids and Lipoproteins in Children and Adolescents. Endocrinology and Metabolism Clinics of North America, 2022, 51, 573-588.	1.2	1
1187	Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical Drug Investigation, 2022, 42, 643-656.	1.1	5
1188	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. Journal of Clinical Medicine, 2022, 11, 3884.	1.0	22
1189	The relation between coronary artery disease and newly diagnosed dysglycemia. Perfusion (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.5	0
1191	Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk. Current Cardiovascular Risk Reports, 0, , .	0.8	0
1192	Associations between the HDL-C/ApoA-I ratio and fasting glucose levels differ by glucose deciles, HDL-C/ApoA-I ratio ranges and sex. Diabetes Research and Clinical Practice, 2022, 190, 110021.	1.1	1
1193	Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes. Cardiovascular Research, 2023, 119, 826-834.	1.8	10

#	Article	IF	Citations
1194	Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Review of Cardiovascular Therapy, 2022, 20, 609-625.	0.6	7
1195	Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials. Frontiers in Pharmacology, 0, 13, .	1.6	2
1196	Association between statin use and the prognosis of patients with acute myocardial infarction complicated with diabetes. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1197	Effect of CSL112 (apolipoprotein Aâ€‰[human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a crossâ€‰study comparison. Clinical and Translational Science, 0, , .	1.5	3
1198	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	78
1199	Monocyte to high-density lipoprotein ratio predict long-term clinical outcomes in patients with coronary heart disease: A meta-analysis of 9 studies. Medicine (United States), 2022, 101, e30109.	0.4	9
1200	Colesevelam â€“ a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. Expert Opinion on Pharmacotherapy, 2022, 23, 1363-1370.	0.9	2
1201	The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I. Best Practice and Research in Clinical Endocrinology and Metabolism, 2023, 37, 101689.	2.2	3
1202	Non-innocuous Consequences of Metabolic Oxidation of Alkyls on Arenes. Journal of Medicinal Chemistry, 2022, 65, 11433-11453.	2.9	1
1203	HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism. Journal of Pharmacological Sciences, 2022, 150, 81-89.	1.1	9
1204	Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology, 2023, 17, 19-39.	0.6	24
1205	Biomarkers in Disease: Diabetes Methods, Discoveries and Applications. Biomarkers in Disease, 2022, , 1-16.	0.0	0
1206	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2022, 16, e77-e95.	0.6	16
1207	Long-Term Exposure to Ambient Fine Particulate Matter and Incidence of Major Cardiovascular Diseases: A Prospective Study of 0.5 Million Adults in China. Environmental Science & Technology, 2022, 56, 13200-13211.	4.6	22
1208	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 2022, 43, 3925-3946.	1.0	290
1209	Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury. JCI Insight, 2022, 7, .	2.3	3
1210	New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4281-e4294.	1.8	5
1211	Biomarkers in Disease: Diabetes Methods, Discoveries, and Applications. Biomarkers in Disease, 2023, , 395-409.	0.0	0

#	Article	IF	Citations
1212	New algorithms for treating homozygous familial hypercholesterolemia. Current Opinion in Lipidology, 2022, 33, 326-335.	1.2	9
1214	CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842211215.	1.0	6
1215	Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. Journal of Clinical Medicine, 2022, 11, 6040.	1.0	14
1216	Benefits of Streamlined Point-of-Care Trial Designs. JAMA Internal Medicine, 2022, 182, 1243.	2.6	10
1217	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	1
1218	Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	28
1219	Nutraceuticals for targeting NAD+ to restore mitochondrial function. , 2023, , 433-460.		0
1220	Guidelines, Clinical Evidence, and Real-Life Practice: How to Find Your Way in Managing Hypercholesterolaemia. EMJ Cardiology, 0, , 38-46.	0.0	0
1221	Can we revive CETP-inhibitors for the prevention of cardiovascular disease?. Current Opinion in Lipidology, 2022, 33, 319-325.	1.2	7
1222	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad EspaÃ±ola de CardiologÃa [Spanish Society of Cardiology] and the Sociedad EspaÃ±ola de Diabetes [Spanish Diabetes Society]. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2023, 70, 51-62.	0.1	0
1223	Lipoprotein(a) and Cardiovascular Disease in Chinese Population. JACC Asia, 2022, 2, 653-665.	0.5	14
1224	Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
1225	Association between niacin and mortality among patients with cancer in the NHANES retrospective cohort. BMC Cancer, 2022, 22, .	1.1	3
1228	Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial). American Journal of Cardiology, 2023, 187, 10-17.	0.7	8
1229	Niacin. , 2024, , 755-761.		0
1230	Aloe vera in diabetic dyslipidemia: Improving blood glucose and lipoprotein levels in pre-clinical and clinical studies. Journal of Ayurveda and Integrative Medicine, 2022, 13, 100675.	0.9	5
1231	Lipid lowering therapy in 2022 and beyond - How far we have come. Progress in Cardiovascular Diseases, 2022, 75, 1-3.	1.6	5
1232	Hibernation or Transformation? Challenges in Cardiovascular Drug Development. Frontiers in Cardiovascular Drug Discovery, 2022, , 102-140.	0.0	0

#	Article	IF	Citations
1233	Impact of High-Density Lipoprotein Function, Rather Than High-Density Lipoprotein Cholesterol Level, on Cardiovascular Disease Among Patients With Familial Hypercholesterolemia. Circulation Journal, 2023, 87, 806-812.	0.7	4
1234	Coronary artery calcium scoring as a tool for risk stratification in patients with an elevated lipoprotein(a) level. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
1235	Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option. International Journal of Molecular Sciences, 2023, 24, 170.	1.8	5
1236	Interrelationships among plateletâ€activating factor and lipoproteinâ€associated phospholipase <scp>A₂</scp> activity and traditional cardiovascular risk factors. BioFactors, 2023, 49, 457-471.	2.6	4
1237	The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2022, , .	0.4	1
1238	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€”2023. Diabetes Care, 2023, 46, S158-S190.	4.3	156
1239	Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle?. Current Opinion in Endocrinology, Diabetes and Obesity, 0, Publish Ahead of Print, .	1.2	2
1240	The need for new clinical trials of old cardiovascular drugs. Nature Reviews Cardiology, 0, , .	6.1	0
1241	Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study. Frontiers in Pharmacology, 0, 13, .	1.6	3
1242	HDL Functionsâ€”Current Status and Future Perspectives. Biomolecules, 2023, 13, 105.	1.8	12
1243	Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current Atherosclerosis Reports, 2023, 25, 1-17.	2.0	28
1245	Lp(a) - an overlooked risk factor. Trends in Cardiovascular Medicine, 2023, , .	2.3	2
1246	Improving Cardiovascular Risk Assessment to Optimize Therapy. World Journal of Cardiovascular Diseases, 2023, 13, 7-20.	0.0	1
1247	Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments. Expert Review of Clinical Pharmacology, 2023, 16, 97-99.	1.3	1
1248	Comparison of the effects of 3 kinds of oils rich in omega-3 polyunsaturated fatty acids on glycolipid metabolism and lipoprotein subfractions. Food Science and Human Wellness, 2023, 12, 2221-2231.	2.2	1
1249	Development and validation of novel automatable assay for cholesterol efflux capacity. Bioscience Reports, 2023, 43, .	1.1	1
1250	What is really new in triglyceride guidelines?. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 73-80.	1.2	0
1251	Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. Journal of Clinical Medicine, 2023, 12, 1382.	1.0	2

#	Article	IF	Citations
1252	Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 387-398.	1.4	2
1253	Association of Dietary Niacin Intake with Diabetes in Adults in the United States. Experimental and Clinical Endocrinology and Diabetes, 2023, 131, 354-361.	0.6	1
1254	HDL-Based Therapy: Vascular Protection at All Stages. Biomedicines, 2023, 11, 711.	1.4	1
1255	Therapy of Elevated Lipoprotein(a). Contemporary Cardiology, 2023, , 347-357.	0.0	0
1256	HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS. International Journal of Molecular Sciences, 2023, 24, 5391.	1.8	1
1257	Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies. Journal of Nephrology, 2023, 36, 1549-1559.	0.9	3
1258	A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease. Reviews in the Neurosciences, 2023, .	1.4	0
1259	San-wei-tan-xiang capsule attenuates atherosclerosis by increasing lysosomal activity in adipose tissue macrophages. Journal of Ethnopharmacology, 2023, 312, 116444.	2.0	1
1260	Clinical Trial Design for Lipoprotein(a)-Lowering Therapies. Journal of the American College of Cardiology, 2023, 81, 1633-1645.	1.2	18
1261	Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a). , 2022, 1, .		0
1265	Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment. , 2024, , 32-41.e2.		0
1266	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
1270	Managing Stable Coronary Artery Disease in Diabetes. Contemporary Cardiology, 2023, , 655-681.	0.0	0
1271	Diabetes and Atherogenic Dyslipidemia. , 2023, , 645-656.		0
1273	Diabetes and Dyslipidemia. Contemporary Cardiology, 2023, , 425-472.	0.0	3
1278	Clinical Care of Lipids in People with Type 1 Diabetes. Contemporary Diabetes, 2023, , 755-778.	0.0	0
1279	Lipoproteins and Ischemic Stroke in Diabetes. Contemporary Diabetes, 2023, , 503-522.	0.0	0
1280	Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions. Contemporary Diabetes, 2023, , 357-406.	0.0	0

#	Article	IF	Citations
1282	Omega-3 Fatty Acids. , 2024, , 169-183.e3.		0
1283	Special Patient Populations. , 2024, , 345-357.e3.		0
1312	Dyslipidemia in Metabolic Syndrome. , 2023, , 1-18.		0
1317	Cholesterol and lipids. , 2023, , .		0
1324	Omega-3 Fatty Acids Influence Membrane Cholesterol Distribution and Crystal Formation in Models of Atherosclerosis. Contemporary Cardiology, 2023, , 297-318.	0.0	0
1326	HDL as a Treatment Target: Should We Abandon This Idea?. Current Atherosclerosis Reports, 0, , .	2.0	1
1337	Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Current Atherosclerosis Reports, 2024, 26, 35-44.	2.0	2
1339	KardiovaskulÃrer Risikofaktor DyslipidÃmie. Springer Reference Medizin, 2023, , 161-174.	0.0	0
1340	Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nature Reviews Cardiology, 0, , .	6.1	1
1347	Overview of Inpatient Management of Hypertriglyceridemia Associated Acute Pancreatitis in Patients with Diabetes Mellitus. Contemporary Endocrinology, 2023, , 193-206.	0.3	0
1350	Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy. Current Atherosclerosis Reports, 2024, 26, 103-109.	2.0	0
1351	Dyslipidemia in Metabolic Syndrome. , 2023, , 529-546.		0
1354	A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids. Cardiovascular Drugs and Therapy, 0, , .	1.3	0